1
|
Gill MM, Bakebua W, Ditekemena J, Gbomosa CN, Tshishi D, Loando A, Giri A, Ngantsui RB, Hoffman HJ. Virological and care outcomes of community ART distribution: Experience with the PODI+ model in Kinshasa, Democratic Republic of the Congo. PLOS Glob Public Health 2024; 4:e0002343. [PMID: 38295044 PMCID: PMC10830041 DOI: 10.1371/journal.pgph.0002343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 12/12/2023] [Indexed: 02/02/2024]
Abstract
INTRODUCTION Differentiated service delivery models for HIV treatment can minimize unnecessary burdens on health systems and promote efficient delivery of antiretroviral therapy (ART). Under the PODI+ (poste de distribution communautaire) model, ART multi-month dispensation (MMD) was provided by lay workers (peers) in communities. We compared outcomes among clinically stable adults living with HIV receiving MMD via PODI+ or health facility (HF). METHODS Clients receiving MMD at nine HFs and two PODI+ sites in Kinshasa were followed prospectively for one year (2018-2020). Medication possession ratio (MPR) was measured as proportion of total days with medication during the study through record abstraction at 3-month intervals. Viral load was assessed at enrollment and 12 months. We compared MPR and viral load suppression by arm and examined associations and potential confounders using unadjusted and adjusted odds ratios (AOR). Likert-style client satisfaction was collected during 12-month interviews and described by arm. RESULTS Odds of maintaining viral load suppression at 12 months for PODI+ participants were two times that for HF participants. In adjusted models, PODI+ participants had 1.89 times the odds of being suppressed at 12 months compared to HF participants (95% CI: 1.10, 3.27). No significant differences in MPR were found between groups (OR: 0.86, 0.38-1.99). Older participants had significantly higher odds of MPR (AOR: 1.02, 95% CI: 1.01, 1.03) and viral suppression (AOR: 1.03, 95% CI: 1.00, 1.07). Satisfaction with services was ≥87% overall, but PODI+ participants rated time spent at site, provider attributes and other care aspects more favorably. CONCLUSIONS Participants receiving MMD via peer-run community distribution points had similar MPR, but better virological outcomes and greater satisfaction with care than clinically similar participants receiving MMD through facilities. PODI+ could be a useful model for expansion to serve larger clinic populations from overburdened health facilities, particularly as policy shifts towards more inclusive MMD eligibility requirements.
Collapse
Affiliation(s)
- Michelle M. Gill
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, United States of America
| | - Winnie Bakebua
- Elizabeth Glaser Pediatric AIDS Foundation, Kinshasa, Democratic Republic of the Congo
| | - John Ditekemena
- Elizabeth Glaser Pediatric AIDS Foundation, Kinshasa, Democratic Republic of the Congo
| | | | - Dieudonné Tshishi
- Elizabeth Glaser Pediatric AIDS Foundation, Kinshasa, Democratic Republic of the Congo
| | - Aimé Loando
- Elizabeth Glaser Pediatric AIDS Foundation, Kinshasa, Democratic Republic of the Congo
| | - Abhigya Giri
- Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, United States of America
| | - Roger Beni Ngantsui
- DRC Ministry of Health, National AIDS Control Program, Kinshasa, Democratic Republic of the Congo
| | - Heather J. Hoffman
- Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, United States of America
| |
Collapse
|
2
|
Gill MM, Khumalo P, Chouraya C, Kunene M, Dlamini F, Hoffman HJ, Scheuerle AE, Nhlabatsi B, Mngometulu W, Dlamini-Madlopha N, Mthunzi N, Mofenson L. Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini. Open Forum Infect Dis 2023; 10:ofad441. [PMID: 37720700 PMCID: PMC10502921 DOI: 10.1093/ofid/ofad441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 08/15/2023] [Indexed: 09/19/2023] Open
Abstract
Birth defect surveillance in Eswatini in 2020-2021 identified 0.80% defects (197/24 599 live and stillborn infants). Neural tube defect (NTD) prevalence was 0.08%, 0.08%, and 0.15% for 4902 women on dolutegravir preconception, 17 285 HIV-negative women, and 1320 women on efavirenz preconception, respectively, more definitively refuting the dolutegravir preconception NTD safety signal.
Collapse
Affiliation(s)
- Michelle M Gill
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA
| | | | | | | | - Futhi Dlamini
- Elizabeth Glaser Pediatric AIDS Foundation, Mbabane, Eswatini
| | - Heather J Hoffman
- Department of Biostatistics and Bioinformatics, Milken School of Public Health, George Washington University, Washington, DC, USA
| | | | | | | | | | | | - Lynne Mofenson
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA
| |
Collapse
|
3
|
Antelman G, Ferla J, Gill MM, Hoffman HJ, Komba T, Abubakar A, Remes P, Jahanpour O, Mariki M, Mang’enya MA, van de Ven R. Effectiveness of an integrated multilevel early child development intervention on caregiver knowledge and behavior: a quasi-experimental evaluation of the Malezi program in Tanzania. BMC Public Health 2023; 23:19. [PMID: 36600280 PMCID: PMC9811787 DOI: 10.1186/s12889-022-14956-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2022] [Accepted: 12/28/2022] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND The quality of caregiving and the parent-child relationship is critical for early child development (ECD) and has been shown to be modifiable. This study evaluated an ECD project in Tanzania, assessing the effectiveness of radio messaging (RM) alone and a combined radio messaging/video job aids/ECD (RMV-ECD) intervention. METHODS This two-arm pre-post evaluation study enrolled a cohort of caregivers of children 0-24 months in four districts of Tabora region, following them for 9 months. ECD radio messages were broadcast on popular stations at least 10 times/day reaching all study districts. In two districts, community health workers (CHW), trained in UNICEF's Care for Child Development package, used ECD videos in home- and facility-based sessions with caregivers. We used McNemar's testing (pre-post pairs) within intervention group to describe how the intervention was associated with change in five outcomes: ECD knowledge, early stimulation, father engagement, responsive care, and environment safety. Logistic regression was used to describe the relative benefits of the combined intervention package (RMV-ECD) compared to radio messaging (RM). RESULTS In the RMV-ECD arm, all outcomes at endline except environment safety significantly improved after the intervention with the largest change seen in ECD knowledge (35.8% increase, p < .0001) and the smallest in father engagement (6.7%, p = .015). In the RM arm, ECD knowledge (5.7%, p = .031) and environment safety (18.1%, p = <.0001) improved. High measures of parenting stress were associated with lower likelihood of having good ECD knowledge (AOR 0.50, 95%CI: 0.35, 0.71), father engagement (AOR 0.72, 95%CI: 0.52, 0.99) and responsive care (AOR 0.31, 95%CI: 0.18, 0.54). CONCLUSIONS An intervention that includes mass media, educational video content and CHWs who counsel caregivers in their homes and health facilities was associated with significant improvements in ECD parenting knowledge and behaviors but a relationship with responsive care could not be established. The less costly mass media-only intervention was associated with improved parenting knowledge and household environment safety. Parenting interventions targeting young children could be improved by incorporating more messaging and caregiver coaching in managing parental stress. TRIAL REGISTRATION NCT05244161 (17/02/2022); retrospectively registered with the US National Institutes of Health ClinicalTrials.gov.
Collapse
Affiliation(s)
- Gretchen Antelman
- grid.463111.0Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania
| | - Josephine Ferla
- grid.463111.0Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania
| | - Michelle M. Gill
- grid.420931.d0000 0000 8810 9764Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, USA
| | - Heather J. Hoffman
- grid.253615.60000 0004 1936 9510The George Washington University, Milken Institute School of Public Health Washington DC, Washington DC, USA
| | - Teopista Komba
- grid.463111.0Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania
| | - Amina Abubakar
- grid.470490.eInstitute for Human Development Aga Khan University (South-Central Asia, East Africa, UK), Nairobi, Kenya
| | - Pieter Remes
- Development Media International, Mwanza, Tanzania
| | - Ola Jahanpour
- grid.463111.0Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania
| | - Martha Mariki
- President’s Office Regional and Local Government, Dodoma, Tanzania
| | - Mary A. Mang’enya
- grid.415734.00000 0001 2185 2147Ministry of Health, Dodoma, Tanzania
| | - Roland van de Ven
- grid.463111.0Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania
| |
Collapse
|
4
|
Harris LR, Hoffman HJ, Griffith CJ, Lee N, Koay WLA, Rakhmanina NY. Factors Associated with Transition of HIV Care Readiness Among Adolescents and Youth from a Specialty Pediatric HIV Clinic in the United States. AIDS Patient Care STDS 2021; 35:495-502. [PMID: 34851725 DOI: 10.1089/apc.2021.0123] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Transitioning from pediatric to adult services is known to be associated with worsening of health outcomes and decreased retention in care among adolescents and youth living with HIV (AYLHIV). We aimed to identify factors associated with HIV care transition readiness among AYLHIV in care at a pediatric HIV clinic in Washington, DC. This retrospective cohort study from June 2019 through January 2021 collected demographic and clinical characteristics from the clinic database. We adapted the Transition Readiness Assessment Questionnaire (TRAQ; scored 1-4; 1 being the lowest level of preparedness) to evaluate transition readiness over time. We analyzed data using two-sided unadjusted two-sample and paired t-tests and adjusted analysis of variance (ANOVA). We included 103 AYLHIV (50.49% female; 100% non-Hispanic Black/African American; mean age = 19.54 ± 2.78 years; 81.55% virally suppressed). Mean baseline TRAQ score (2.32 ± 0.78) was associated with age (p < 0.0001), gender (p = 0.033), mode of HIV transmission (p = 0.0005), viral suppression (p = 0.0033), and duration of HIV diagnosis (p = 0.012). AYLHIV diagnosed with HIV within the prior year experienced significantly greater mean improvement in transition readiness compared with those living with HIV for >10 years (p = 0.013). Adjusted for covariates, older age (p < 0.0001), undetectable viral load (p = 0.0008), and presence of mental health condition(s) (p = 0.020) were associated with higher TRAQ scores. Lower improvement in transition readiness among youth with a longer history of HIV suggests that AYLHIV with perinatally acquired HIV might require additional support than those with horizontally acquired HIV.
Collapse
Affiliation(s)
- Leah R. Harris
- Department of Epidemiology, The George Washington University Milken Institute School of Public Health, Washington, District of Columbia, USA
- HIV and Special Immunology Services, Children's National Hospital, Washington, District of Columbia, USA
| | - Heather J. Hoffman
- Department of Biostatistics and Bioinformatics, The George Washington University Milken Institute School of Public Health, Washington, District of Columbia, USA
| | - Caleb J. Griffith
- HIV and Special Immunology Services, Children's National Hospital, Washington, District of Columbia, USA
| | - Nara Lee
- HIV and Special Immunology Services, Children's National Hospital, Washington, District of Columbia, USA
| | - Wei Li A. Koay
- HIV and Special Immunology Services, Children's National Hospital, Washington, District of Columbia, USA
- Division of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA
- Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA
| | - Natella Y. Rakhmanina
- HIV and Special Immunology Services, Children's National Hospital, Washington, District of Columbia, USA
- Division of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA
- Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA
- Technical Strategies and Innovation, Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, USA
| |
Collapse
|
5
|
Tukei VJ, Hoffman HJ, Greenberg L, Thabelo R, Nchephe M, Mots’oane T, Masitha M, Chabela M, Mokone M, Mofenson L, Guay L, Tiam A. Adverse Pregnancy Outcomes Among HIV-positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated Compared With HIV-negative Women. Pediatr Infect Dis J 2021; 40:821-826. [PMID: 33990522 PMCID: PMC8357042 DOI: 10.1097/inf.0000000000003174] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/27/2021] [Indexed: 11/26/2022]
Abstract
BACKGROUND Without treatment, HIV infection in pregnant women is associated with adverse pregnancy outcomes. We compared adverse pregnancy outcomes among HIV-positive women on antiretroviral therapy (ART) and HIV-negative women who enrolled for antenatal care in selected health facilities in Maseru district, Lesotho. METHODS We enrolled a cohort of HIV-positive and HIV-negative women at their first antenatal visit and followed them through delivery. Study data on miscarriage, stillbirth, preterm birth, low birth weight and birth defects were collected through participant interviews and medical record abstraction. We used the Rao-Scott χ2 test and the t test to assess differences in characteristics and outcomes between HIV-positive and HIV-negative women and generalized estimating equations for multivariable analysis. RESULTS A total of 614 HIV-positive and 390 HIV-negative pregnant women were enrolled in the study with delivery information on 571 (93.1%) and 352 (90.3%) respectively. In the delivery cohort, the median age at enrolment was 28 years for HIV-positive women and 23 years for HIV-negative women with median gestational ages of 20 and 21 weeks, respectively. A total of 149 singleton pregnancies had documented adverse pregnancy outcomes; 33 (9.6%) HIV-negative pregnancies and 116 (20.6%) HIV-positive pregnancies. Compared with their HIV-negative counterparts, HIV-positive women were more likely to experience an adverse pregnancy outcome, adjusted odds ratio (AOR) 2.6 [95% confidence interval (CI): 1.71-3.97]; an intrauterine death (miscarriage or stillbirth), AOR 2.64 [95% CI: 1.25-5.49]; or a low birth weight delivery, AOR 1.89 [95% CI: 1.16-3.09]. CONCLUSION Adverse pregnancy outcomes remained 2-3 times higher among HIV-positive women compared with HIV-negative women despite universal ART.
Collapse
Affiliation(s)
- Vincent J. Tukei
- From the Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho
| | - Heather J. Hoffman
- Department of Biostatistics and Bioinformatics, George Washington University Milken Institute School of Public Health, Washington, District of Columbia
| | - Lauren Greenberg
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia
| | | | | | | | - Matseliso Masitha
- From the Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho
| | - Mammatli Chabela
- From the Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho
| | - Majoalane Mokone
- From the Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho
| | - Lynne Mofenson
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia
| | - Laura Guay
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia
- Department of Epidemiology, George Washington University Milken Institute School of Public Health, Washington, District of Columbia
| | - Appolinaire Tiam
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia
- Department of global public health and primary care, Center for International Health, University of Bergen, Bergen, Norway
| |
Collapse
|
6
|
Mouhanna F, Castel AD, Sullivan PS, Kuo I, Hoffman HJ, Siegler AJ, Jones JS, Mera Giler R, McGuinness P, Kramer MR. Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018. Ann Epidemiol 2020; 49:1-7. [PMID: 32951802 DOI: 10.1016/j.annepidem.2020.07.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 06/30/2020] [Accepted: 07/01/2020] [Indexed: 11/25/2022]
Abstract
PURPOSE Oral emtricitabine/tenofovir disoproxil fumarate was approved for use as pre-exposure prophylaxis (PrEP) by the U.S. Food and Drug Administration in 2012. We used national pharmacy data to examine trends of PrEP use in U.S. counties from 2012 to 2018. METHODS Using multi-level small-area spatio-temporal modeling, we calculated the estimated annual percentage change (EAPC) in prevalence of PrEP use in the general population from 2012 to 2018. We also used a proxy measure for prevalence of PrEP use among men who have sex with men (MSM) to evaluate trends of use among MSM, the PrEP use-to-MSM ratio (PmR) or number of male PrEP users per 1000 MSM population. RESULTS The prevalence of PrEP use and PmR increased (EAPC range: (+26.9%, +71.0%) and (+28.4%, +158.7%), respectively) in all counties with varying magnitude of increase. Counties of the Midwest and the upper South and upper West had the slowest increase in prevalence of PrEP use (EAPC range: (+26.9%; +52.9%)). Counties of the northern part of the South had the lowest PmR (EAPC range: (+28.4%; +76.0%)). Counties of the most populous core-based statistical areas had a relatively faster increase in population prevalence of PrEP use but slower increase in PmR. CONCLUSIONS All counties in the U.S. have witnessed an increase in PrEP use with important geographic variabilities. Identifying areas with slow improvement in PrEP use, as well as "model counties" with the fastest pace of progress in PrEP coverage, is critical to inform local and state-level policies and program evaluation for PrEP scale up, particularly among MSM at higher risk for HIV.
Collapse
Affiliation(s)
- Farah Mouhanna
- Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA; Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC
| | - Amanda D Castel
- Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC
| | - Patrick S Sullivan
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
| | - Irene Kuo
- Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC
| | - Heather J Hoffman
- Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Washington, DC
| | - Aaron J Siegler
- Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA
| | - Jeb S Jones
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
| | | | | | - Michael R Kramer
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
| |
Collapse
|
7
|
Gill MM, Hoffman HJ, Ndatimana D, Mugwaneza P, Guay L, Ndayisaba GF, Bobrow EA, Asiimwe A, Mofenson LM. 24-month HIV-free survival among infants born to HIV-positive women enrolled in Option B+ program in Kigali, Rwanda: The Kabeho Study. Medicine (Baltimore) 2017; 96:e9445. [PMID: 29390577 PMCID: PMC5758279 DOI: 10.1097/md.0000000000009445] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Lifelong antiretroviral therapy (ART) provision to all pregnant HIV-positive women ("Option B+") has been recommended by the World Health Organization since 2013, but there remain limited data on the effects of Option B+ on long-term HIV-free survival in breastfeeding HIV-exposed infants. The Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV (Kabeho) study enrolled HIV-positive women from the third trimester of pregnancy to 2 weeks postpartum in 14 heath facilities implementing Option B+ in Kigali, Rwanda. Mother-child pairs in the longitudinal observational cohort were followed until 24 months postpartum, with HIV diagnostic testing at 6 weeks, and 9, 18 and 24 months. The Kaplan-Meier method was used to estimate HIV transmission, survival, and HIV-free survival through 24 months. We enrolled 608 HIV-positive women in 2013-2014; birth outcome data were available for 600 women and 597 live-born infants. By 6 weeks, 11 infants had died and 3 infants had confirmed HIV infection (0.5% transmission; 95% confidence interval [CI] 0.2-1.6). At 9 months, there were 9 additional deaths and 2 new infections (cumulative transmission 0.9%, 95% CI 0.4-2.2). At 18 months, there were 6 additional deaths and no new infant infections. At 24 months, there were no additional child deaths and 1 new infection (cumulative 2.2%, 95% CI 0.7-7.0), for an overall 24-month HIV-free survival of 93.2% (95% CI 89.5-95.6). Low transmission rates and high HIV-free survival at 24 months were achieved in breastfeeding infants of HIV-positive mothers receiving universal ART in urban health facilities in Rwanda, though vigilance on maintaining viral suppression for ART-experienced women is needed.
Collapse
Affiliation(s)
| | - Heather J. Hoffman
- Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC
| | | | | | - Laura Guay
- Elizabeth Glaser Pediatric AIDS Foundation
- Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC
| | | | | | - Anita Asiimwe
- Rwanda University Teaching Hospitals (CHU), Kigali, Rwanda
| | | |
Collapse
|
8
|
Tiam A, Gill MM, Hoffman HJ, Isavwa A, Mokone M, Foso M, Safrit JT, Mofenson LM, Tylleskär T, Guay L. Conventional early infant diagnosis in Lesotho from specimen collection to results usage to manage patients: Where are the bottlenecks? PLoS One 2017; 12:e0184769. [PMID: 29016634 PMCID: PMC5634554 DOI: 10.1371/journal.pone.0184769] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Accepted: 08/30/2017] [Indexed: 11/18/2022] Open
Abstract
Introduction Early infant diagnosis is an important step in identifying children infected with HIV during the perinatal period or in utero. Multiple factors contribute to delayed antiretroviral treatment initiation for HIV-infected children, including delays in the early infant HIV diagnosis cascade. Methods We conducted a retrospective study to evaluate early infant diagnosis turnaround times in Lesotho. Trained staff reviewed records of HIV-exposed infants (aged-6-8 weeks) who received an HIV test during 2011. Study sites were drawn from Highlands, Foothills and Lowlands regions of Lesotho. Central laboratory database data were linked to facility and laboratory register information. Turnaround time geometric means (with 95% CI) were calculated and compared by region using linear mixed models. Results 1,187 individual infant records from 25 facilities were reviewed. Overall, early infant diagnosis turnaround time was 61.7 days (95%CI: 55.3–68.7). Mean time from specimen collection to district laboratory was 14 days (95%CI: 12.1–16.1); from district to central laboratory, 2 days (95%CI 0.8–5.2); results from central laboratory to district hospital, 23.3 days (95%CI: 18.7–29.0); from district hospital to health facility, 3.2 days (95%CI 1.9–5.5); and from health facility to caregiver, 10.4 days (95%CI, 7.9–13.5). Mean times from specimen transfer to the central laboratory and for result transfer from central laboratory to district hospital were significantly shorter in the Lowlands Region (0.9 and 16.2 days, respectively), compared to Highlands Region (6.0 [P = 0.030] and 34.3 days [P = 0.0099]. Turnaround time from blood draw to receipt of results was significantly shorter for HIV infected infants compared to HIV uninfected infants [p = 0.0036] at an average of 47.1 days (95%CI: 38.9–56.9) and 62 days (95%CI: 55.9–68.7) respectively. Of 47 HIV-infected infants, 36 were initiated on antiretroviral therapy at an average of 1.3 days (95%CI: 0.3, 5.7) after caregiver received the result. Conclusion HIV-infected infants received results earlier and were rapidly initiated on antiretroviral therapy once the result was delivered to caregiver. However, average early infant diagnosis turnaround time was two months; the longest period of delay was transfer of results from central laboratory to district hospital. Turnaround time of results based on geographical regions or between hospitals and health centres varied but did not reach statistical significance.
Collapse
Affiliation(s)
- Appolinaire Tiam
- Centre for International Health, University of Bergen, Bergen, Norway
- Medical and Scientific Affairs, Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho
- * E-mail: ,
| | - Michelle M. Gill
- Research, Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, United States of America
| | - Heather J. Hoffman
- Milken Institute School of Public Health, George Washington University, Washington DC, United States of America
| | - Anthony Isavwa
- Medical and Scientific Affairs, Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho
| | - Mafusi Mokone
- Medical and Scientific Affairs, Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho
| | - Matokelo Foso
- Medical and Scientific Affairs, Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho
| | - Jeffrey T. Safrit
- Research Alliances, International AIDS Vaccine Initiative, New York, New York, United States of America
| | - Lynne M. Mofenson
- Research, Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, United States of America
| | | | - Laura Guay
- Research, Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, United States of America
- Milken Institute School of Public Health, George Washington University, Washington DC, United States of America
| |
Collapse
|
9
|
Erlandson KM, Plankey MW, Springer G, Cohen HS, Cox C, Hoffman HJ, Yin MT, Brown TT. Fall frequency and associated factors among men and women with or at risk for HIV infection. HIV Med 2017; 17:740-748. [PMID: 27028463 DOI: 10.1111/hiv.12378] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/06/2016] [Indexed: 11/28/2022]
Abstract
OBJECTIVES Falls and fall-related injuries are a major public health concern. HIV-infected adults have been shown to have a high incidence of falls. Identification of major risk factors for falls that are unique to HIV infection or similar to those in the general population will inform development of future interventions for fall prevention. METHODS HIV-infected and uninfected men and women participating in the Hearing and Balance Substudy of the Multicenter AIDS Cohort Study and Women's Interagency HIV Study were asked about balance symptoms and falls during the prior 12 months. Falls were categorized as 0, 1, or ≥ 2; proportional odds logistic regression models were used to investigate relationships between falls and demographic and clinical variables and multivariable models were created. RESULTS Twenty-four per cent of 303 HIV-infected participants reported at least one fall compared with 18% of 233 HIV-uninfected participants (P = 0.27). HIV-infected participants were demographically different from HIV-uninfected participants, and were more likely to report clinical imbalance symptoms (P ≤ 0.035). In univariate analyses, more falls were associated with hepatitis C, female sex, obesity, smoking, and clinical imbalance symptoms, but not age, HIV serostatus or other comorbidities. In multivariable analyses, female sex and imbalance symptoms were independently associated with more falls. Among HIV-infected participants, smoking, a higher number of medications, and imbalance symptoms remained independent fall predictors, while current protease inhibitor use was protective. CONCLUSIONS Similar rates of falls among HIV-infected and uninfected participants were largely explained by a high prevalence of imbalance symptoms. Routine assessment of falls and dizziness/imbalance symptoms should be considered, with interventions targeted at reducing symptomatology.
Collapse
Affiliation(s)
- K M Erlandson
- Department of Medicine, Divisions of Infectious Diseases and Geriatric Medicine, University of Colorado, Aurora, CO, USA.
| | - M W Plankey
- Department of Medicine, Division of Infectious Diseases, Georgetown University Medical Center, Washington, DC, USA
| | - G Springer
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
| | - H S Cohen
- Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
| | - C Cox
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
| | - H J Hoffman
- Epidemiology and Statistics Program, National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH), Bethesda, MD, USA
| | - M T Yin
- Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, NY, USA
| | - T T Brown
- Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University, Baltimore, MD, USA
| |
Collapse
|
10
|
Gill MM, Umutoni A, Hoffman HJ, Ndatimana D, Ndayisaba GF, Kibitenga S, Mugwaneza P, Asiimwe A, Bobrow EA. Understanding Antiretroviral Treatment Adherence Among HIV-Positive Women at Four Postpartum Time Intervals: Qualitative Results from the Kabeho Study in Rwanda. AIDS Patient Care STDS 2017; 31:153-166. [PMID: 28358624 DOI: 10.1089/apc.2016.0234] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
As lifelong antiretroviral therapy (ART) for pregnant women is implemented, it is important to understand the attitudes and norms affecting women's postpartum ART adherence. This is a qualitative cross-sectional study of HIV-positive postpartum women (n = 112) enrolled in a 2-year observational prospective cohort in Rwanda. Informed by the Theory of Reasoned Action (TRA), we conducted in-depth interviews with women whose children were 0-6, 7-12, 13-18, or 21-24 months of age to describe factors contributing to adherence and changes over time. Positive ART attitudes reported by women included mothers' health promotion, prevention of infant HIV infection, higher CD4 count, and improved physical appearance. Negative attitudes were few, but included side effects and the lifelong nature of treatment. Learning from people living with HIV (PLHIV) was identified as a norm facilitating adherence; ART adherence was inhibited by fear of disclosure or stigmatization in communities and clinics. Poor adherence behaviors were common immediately after HIV diagnosis, not necessarily during prevention of mother-to-child transmission (PMTCT). Women with older children, most of whom stopped breastfeeding by 13-18 months, reported more barriers and missed doses than women with younger children. The TRA was useful in identifying the collective influence of attitudes, norms, and intentions on behavior. Findings suggest that HIV-positive women are vulnerable to poor adherence following HIV diagnosis and around the time of breastfeeding cessation. Lifelong treatment adherence can be supported through PLHIV exemplifying long-term ART use, fewer and less stigmatizing clinic visits, and counseling messages highlighting the benefits of drugs on appearance and illness prevention and incorporating biological feedback.
Collapse
Affiliation(s)
- Michelle M. Gill
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia
| | - Aline Umutoni
- Elizabeth Glaser Pediatric AIDS Foundation, Kigali, Rwanda
| | - Heather J. Hoffman
- Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia
| | | | | | | | | | - Anita Asiimwe
- Rwanda University Teaching Hospitals (CHU), Kigali, Rwanda
| | - Emily A. Bobrow
- MEASURE Evaluation, University of North Carolina, Chapel Hill, North Carolina
| |
Collapse
|
11
|
Gill MM, Hoffman HJ, Bobrow EA, Mugwaneza P, Ndatimana D, Ndayisaba GF, Baribwira C, Guay L, Asiimwe A. Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study. PLoS One 2016; 11:e0168671. [PMID: 28006001 PMCID: PMC5179044 DOI: 10.1371/journal.pone.0168671] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Accepted: 12/05/2016] [Indexed: 12/13/2022] Open
Abstract
There are limited viral load (VL) data available from programs implementing “Option B+,” lifelong antiretroviral treatment (ART) to all HIV-positive pregnant and postpartum women, in resource-limited settings. Extent of viral suppression from a prevention of mother-to-child transmission of HIV program in Rwanda was assessed among women enrolled in the Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV (Kabeho) Study. ARV drug resistance testing was conducted on women with VL>2000 copies/ml. In April 2013-January 2014, 608 pregnant or early postpartum HIV-positive women were enrolled in 14 facilities. Factors associated with detectable enrollment VL (>20 copies/ml) were examined using generalized estimating equations. The most common antiretroviral regimen (56.7%, 344/607) was tenofovir/lamivudine/efavirenz. Median ART duration was 13.5 months (IQR 3.0–48.8); 76.1% of women were on ART at first antenatal visit. Half of women (315/603) had undetectable RNA-PCR VL and 84.6% (510) had <1,000 copies/ml. Detectable VL increased among those on ART > 36 months compared to those on ART 4–36 months (72/191, 37.7% versus 56/187, 29.9%), though the difference was not significant. The odds of having detectable enrollment VL decreased significantly as duration on ART at enrollment increased (AOR = 0.99, 95% CI: 0.9857, 0.9998, p = 0.043). There was a higher likelihood of detectable VL for women with lower gravidity (AOR = 0.90, 95% CI: 0.84, 0.97, p = 0.0039), no education (AOR = 2.25, (95% CI: 1.37, 3.70, p = 0.0004), nondisclosure to partner (AOR = 1.97, 95% CI: 1.21, 3.21, p = 0.0063) and side effects (AOR = 2.63, 95% CI: 1.72, 4.03, p<0.0001). ARV drug resistance mutations were detected in all of the eleven women on ART > 36 months with genotyping available. Most women were receiving ART at first antenatal visit, with relatively high viral suppression rates. Shorter ART duration was associated with higher VL, with a concerning increasing trend for higher viremia and drug resistance among women on ART for >3 years.
Collapse
Affiliation(s)
- Michelle M. Gill
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, United States of America
- * E-mail:
| | - Heather J. Hoffman
- Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, United States of America
| | - Emily A. Bobrow
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, United States of America
| | | | | | | | - Cyprien Baribwira
- University of Maryland, Baltimore, Maryland, United States of America
| | - Laura Guay
- Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, United States of America
- Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, United States of America
| | - Anita Asiimwe
- Rwanda University Teaching Hospitals, Kigali, Rwanda
| |
Collapse
|
12
|
Levine PH, Ajmera K, O’Neill B, Venkatesh V, Garcia-Gonzalez P, Hoffman HJ. Demographic factors related to young age at diagnosis of chronic myeloid leukemia in India. Clinical Epidemiology and Global Health 2016. [DOI: 10.1016/j.cegh.2016.06.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
13
|
Zhou CK, Levine PH, Cleary SD, Hoffman HJ, Graubard BI, Cook MB. Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 2016; 183:210-7. [PMID: 26764224 DOI: 10.1093/aje/kwv190] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Accepted: 07/10/2015] [Indexed: 01/08/2023] Open
Abstract
We used male pattern baldness as a proxy for long-term androgen exposure and investigated the association of dermatologist-assessed hair loss with prostate cancer-specific mortality in the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. From the baseline survey (1971-1974), we included 4,316 men who were 25-74 years of age and had no prior cancer diagnosis. We estimated hazard ratios and used Cox proportional hazards regressions with age as the time metric and baseline hazard stratified by baseline age. A hybrid framework was used to account for stratification and clustering of the sample design, with adjustment for the variables used to calculate sample weights. During follow-up (median, 21 years), 3,284 deaths occurred; prostate cancer was the underlying cause of 107. In multivariable models, compared with no balding, any baldness was associated with a 56% higher risk of fatal prostate cancer (hazard ratio = 1.56; 95% confidence interval: 1.02, 2.37), and moderate balding specifically was associated with an 83% higher risk (hazard ratio = 1.83; 95% confidence interval: 1.15, 2.92). Conversely, patterned hair loss was not statistically significantly associated with all-cause mortality. Our analysis suggests that patterned hair loss is associated with a higher risk of fatal prostate cancer and supports the hypothesis of overlapping pathophysiological mechanisms.
Collapse
|
14
|
Torre P, Zeldow B, Yao TJ, Hoffman HJ, Siberry GK, Purswani MU, Frederick T, Spector SA, Williams PL. Newborn Hearing Screenings in Human Immunodeficiency Virus-Exposed Uninfected Infants. J AIDS Immune Res 2016; 1:102. [PMID: 28459118 PMCID: PMC5407375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Perinatal HIV infection and congenital cytomegalovirus (CMV) infection may increase the risk for hearing loss. We examined 1,435 infants enrolled in the Surveillance Monitoring of ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort Study (PHACS) network, a prospective study of the safety of in utero antiretroviral (ARV) exposures. We determined the proportion of perinatally HIV-exposed uninfected (HEU) newborns who were referred for additional hearing testing, and evaluated the association between in utero ARV exposures and newborn hearing screening results. Using a nested case-control design, we also examined congenital CMV infection in infants with and without screening referral. Congenital CMV infection was determined based on CMV DNA detection using a nested PCR assay in peripheral blood mononuclear cells obtained within 14 days of birth. Among the 1,435 infants (70% black, 31% Hispanic, 51% male), 45 (3.1%) did not pass the hearing screen and were referred for further hearing testing. Based on exact logistic regression models controlling for maternal use of tobacco and ototoxic medications, first trimester exposure to Tenofovir was associated with lower odds of a newborn hearing screening referral [adjusted odds ratio (aOR) = 0.41, 95% confidence interval (CI): 0.14-1.00]. Exposure to Atazanavir was linked to higher odds of newborn screening referral, although not attaining significance [aOR = 1.84, 95% CI: 0.92-3.56]. Maternal ARV use may have varying effects on newborn hearing screenings. These results highlight the importance for audiologists to be knowledgeable of in utero ARV exposures in HEU children because of the possibility of higher referrals in these children.
Collapse
Affiliation(s)
- P Torre
- School of Speech, Language, and Hearing Sciences, San Diego State University, San Diego, CA, USA,Corresponding author: Peter Torre 3rd, School of Speech, Language, and Hearing Sciences, San Diego State University, San Diego, CA 92182-1518, USA. Tel: 619-594-4787, Fax: 619-594-7109;
| | - B Zeldow
- Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA
| | - TJ Yao
- Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA
| | - HJ Hoffman
- Epidemiology and Statistics Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA
| | - GK Siberry
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - MU Purswani
- Albert Einstein College of Medicine, Department of Pediatric Infectious Disease, Bronx-Lebanon Hospital Center, Bronx, NY, USA
| | - T Frederick
- Department of Maternal, Child & Adolescent Center for Infectious Diseases and Virology, University of Southern California, Alhambra, CA, USA
| | - SA Spector
- Department of Pediatrics, University of California San Diego, La Jolla, CA and Rady Children's Hospital San Diego, CA, USA
| | - PL Williams
- Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA
| |
Collapse
|
15
|
Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Levine PH, Hashmi S, Zolfaghari L, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Formenti S, Esteva FJ, Moran MS, Schneider RJ. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. Clin Breast Cancer 2015; 16:113-22.e1. [PMID: 26774497 DOI: 10.1016/j.clbc.2015.11.006] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Revised: 11/09/2015] [Accepted: 11/12/2015] [Indexed: 01/02/2023]
Abstract
INTRODUCTION Inflammatory breast cancer (IBC) is an aggressive and rare cancer with a poor prognosis and a need for novel targeted therapeutic strategies. Preclinical IBC data showed strong activation of the phosphatidylinositide-3-kinase/mammalian target of rapamycin (mTOR) and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways, and expression of inflammatory cytokines and tumor-associated macrophages (TAMs). PATIENTS AND METHODS Archival tumor tissue from 3 disease types (IBC treated with neoadjuvant chemotherapy [NAC], n = 45; invasive ductal carcinoma [IDC] treated with NAC [n = 24; 'treated IDC'; and untreated IDC [n = 27; 'untreated IDC']) was analyzed for the expression of biomarkers phospho-S6 (pS6) (mTOR), phospho-JAK2 (pJAK2), pSTAT3, interleukin (IL)-6, CD68 (monocytes, macrophages), and CD163 (TAMs). Surrounding nontumor tissue was also analyzed. RESULTS Biomarker levels and surrogate activity according to site-specific phosphorylation were shown in the tumor tissue of all 3 disease types but were greatest in IBC and treated IDC and least in untreated IDC for pS6, pJAK2, pSTAT3, and IL-6. Of 37 IBC patients with complete biomarker data available, 100% were pS6-positive and 95% were pJAK2-positive. In nontumor tissue, biomarker levels were observed in all groups but were generally greatest in untreated IDC and least in IBC, except for JAK2. CONCLUSION IBC and treated IDC display similar levels of mTOR and JAK2 biomarker activation, which suggests a potential mechanism of resistance after NAC. Biomarker levels in surrounding nontumor tissue suggested that the stroma might be activated by chemotherapy and resembles the oncogenic tumor-promoting environment. Activation of pS6 and pJAK2 in IBC might support dual targeting of the mTOR and JAK/STAT pathways, and the need for prospective studies to investigate combined targeted therapies in IBC.
Collapse
Affiliation(s)
- Komal Jhaveri
- Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY.
| | - Eleonora Teplinsky
- Division of Hematology & Medical Oncology, Department of Medicine, New York University School of Medicine, New York, NY
| | - Deborah Silvera
- Department of Microbiology, New York University School of Medicine, New York, NY
| | - Amanda Valeta-Magara
- Department of Microbiology, New York University School of Medicine, New York, NY
| | - Rezina Arju
- Department of Microbiology, New York University School of Medicine, New York, NY
| | - Shah Giashuddin
- Department of Pathology, The Brooklyn Hospital Center, Brooklyn, NY
| | - Yasmeen Sarfraz
- Department of Microbiology, New York University School of Medicine, New York, NY
| | | | | | - Paul H Levine
- Department of Epidemiology and Biostatistics, George Washington University, Washington, DC
| | - Salman Hashmi
- Division of Biostatistics, New York University School of Medicine, New York, NY
| | - Ladan Zolfaghari
- Division of Biostatistics, New York University School of Medicine, New York, NY
| | - Heather J Hoffman
- Division of Biostatistics, New York University School of Medicine, New York, NY
| | - Baljit Singh
- Department of Epidemiology and Biostatistics, George Washington University, Washington, DC
| | - Judith D Goldberg
- Division of Biostatistics, New York University School of Medicine, New York, NY
| | - Tsivia Hochman
- Division of Biostatistics, New York University School of Medicine, New York, NY
| | - Silvia Formenti
- Department of Radiation Oncology, Weill Cornell Medical College, New York, NY
| | - Francisco J Esteva
- Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY
| | - Meena S Moran
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT
| | - Robert J Schneider
- Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY; Department of Microbiology, New York University School of Medicine, New York, NY
| |
Collapse
|
16
|
Zhou CK, Levine PH, Cleary SD, Hoffman HJ, Graubard BI, Cook MB. Abstract 4603: Male pattern baldness in relation to prostate cancer-specific mortality: A prospective analysis in the NHANES I Epidemiologic Followup Study (NHEFS). Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-4603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Androgenic action underlies prostate gland development and prostate cancer progression. However, the role of such in prostate carcinogenesis remains unclear. Results from studies that have quantitated pre-diagnostic, circulating androgens at a single time-point in relation to prostate cancer are inconsistent, possibly due to the failure to capture cumulative or relevant age-specific hormone exposure. Therefore, we used male pattern baldness as a proxy of long-term androgen exposure, and investigated the association between dermatologist-assessed male pattern baldness and prostate cancer-specific mortality in the NHANES-I Epidemiologic Followup Study (NHEFS).
Methods: We included 4,316 men from NHEFS, who were 25-74 years, received dermatologic exams, and had no prior cancer diagnosis at baseline. Hazard ratios (HRs) and 95% confidence intervals (95%CIs) were estimated using Cox proportional hazards regression with age as the time-metric and baseline hazard stratified by age at baseline. A hybrid model was used to account for stratification and clustering of the survey design, while adjusting for variables used to calculate sample weights.
Results: During follow-up (median = 21 years), 3,284 deaths occurred, 107 of which had the underlying cause of prostate cancer. Any degree of baldness was associated with a 56% increased risk of prostate cancer-specific mortality (HR = 1.56; 95%CI = 1.02, 2.37) and, specifically, moderate balding was associated with an 83% increased risk of the outcome (HR = 1.83; 95%CI = 1.15, 2.92), each compared with no balding. Conversely, male pattern baldness was not statistically significantly associated with all-cause mortality.
Conclusion: Our analysis suggests that male pattern baldness is associated with an increased risk of fatal prostate cancer, and supports the hypothesis of overlapping pathophysiological mechanisms.
Impact: If the association between male pattern baldness and fatal prostate cancer is substantiated in future studies, male pattern baldness may contribute to predictive algorithms of prostate cancer risk, helping guide individuals as to whether they should opt to undergo cancer screening.
Citation Format: Cindy Ke Zhou, Paul H. Levine, Sean D. Cleary, Heather J. Hoffman, Barry I. Graubard, Michael B. Cook. Male pattern baldness in relation to prostate cancer-specific mortality: A prospective analysis in the NHANES I Epidemiologic Followup Study (NHEFS). [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4603. doi:10.1158/1538-7445.AM2015-4603
Collapse
Affiliation(s)
- Cindy Ke Zhou
- 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
| | - Paul H. Levine
- 2Department of Epidemiology and Biostatistics, George Washington University, Washington, DC
| | - Sean D. Cleary
- 2Department of Epidemiology and Biostatistics, George Washington University, Washington, DC
| | - Heather J. Hoffman
- 2Department of Epidemiology and Biostatistics, George Washington University, Washington, DC
| | - Barry I. Graubard
- 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
| | - Michael B. Cook
- 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
| |
Collapse
|
17
|
|
18
|
|
19
|
|
20
|
Zhou CK, Littman AJ, Levine PH, Hoffman HJ, Cleary SD, White E, Cook MB. Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study. Prostate 2015; 75:415-23. [PMID: 25492530 PMCID: PMC4293210 DOI: 10.1002/pros.22927] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Accepted: 09/30/2014] [Indexed: 11/08/2022]
Abstract
BACKGROUND Male pattern baldness and prostate cancer may share common pathophysiological mechanisms in terms of advancing age, heritability, and endogenous hormones. Results from previous epidemiologic studies are inconsistent. Therefore, we investigated the association of prostate cancer risks with male pattern baldness at age 30 years, age 45 years, and baseline (median age = 60.5 years) in the VITamins And Lifestyle (VITAL) cohort study. METHODS We included 32,583 men who were aged 50-76 years and without prior cancer diagnosis (excluding non-melanoma skin cancer) at the start of follow-up. First primary incident prostate cancers were ascertained via linkage to the western Washington Surveillance, Epidemiology, and End Results (SEER) program. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using Cox proportional hazards regressions with adjustment for potential confounders. RESULTS During follow-up (median = 9 years), 2,306 incident prostate cancers were diagnosed. Male pattern baldness at age 30 years, age 45 years, and baseline were not statistically significantly associated with overall or subtypes of prostate cancer. CONCLUSION This study did not provide support for the hypothesis that male pattern baldness may be a marker for subsequent prostate cancer. Previous evidence indicates that a distinct class of frontal with vertex balding may be associated with increased risk of aggressive prostate cancer, but all such balding classes were captured as a single exposure category by the VITAL cohort questionnaire. Prostate 75:415-423, 2015. © 2014 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Cindy Ke Zhou
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, MD
- Department of Epidemiology and Biostatistics, George Washington University, Washington, D.C
| | - Alyson J. Littman
- Department of Epidemiology, University of Washington, Seattle, WA
- Seattle Epidemiologic Research and Information Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA
| | - Paul H. Levine
- Department of Epidemiology and Biostatistics, George Washington University, Washington, D.C
| | - Heather J. Hoffman
- Department of Epidemiology and Biostatistics, George Washington University, Washington, D.C
| | - Sean D. Cleary
- Department of Epidemiology and Biostatistics, George Washington University, Washington, D.C
| | - Emily White
- Department of Epidemiology, University of Washington, Seattle, WA
- Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Michael B. Cook
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, MD
| |
Collapse
|
21
|
Abstract
OBJECTIVE The association between parity and type 2 diabetes has been studied in developed countries and in Singapore and Chinese women but not in Hispanics. Herein we evaluated the association between parity (number of live births) with diabetes in a group of Hispanic postmenopausal women from Colombia. RESEARCH DESIGN AND METHODS Herein we evaluated the association between parity and diabetes in a population of 1,795 women from Colombia. Women were divided in birth categories (0 [referent], 1 or 2, 3-5, 6 or > births). Medical history of diabetes and anthropometric characteristics were recorded. Logistic regressions were performed in order to find the association between parity and diabetes in bivariable and multivariable models after controlling for age, body mass index (BMI), waist hip ratio (WHR) and diabetes family history, among other variables. RESULTS In our study, there was an association between parity and diabetes after adjusting for age, BMI and diabetes family history in the multiparous women groups when compared to the women with no births (Referent group) [1-2 births vs. referent OR 5.2 (95 CI 1.2-22.9), 3-5 births vs. referent OR 5.5 (1.3-23.0) and ≥6 births vs. referent OR 7.5 (1.8-31.8), respectively]. The association was maintained in two of the groups in the multivariable analysis [OR 5.0 (1.1-22.9) and 5.3 (1.2-23.5)], for 1 or 2 births and 6 or > births versus 0 births, respectively. Positive diabetes family history and WHR were also associated with an increased risk of diabetes [OR 4.6 (3.0-7.0) and 4.1 (2.0-8.1), respectively]. CONCLUSIONS In postmenopausal Hispanic women, multiparity, as well as a positive family history of diabetes and a high waist-hip ratio were associated with higher diabetes risk.
Collapse
Affiliation(s)
- Pablo Cure
- />Children’s National Health System, 111 Michigan Avenue, NW Washington DC, 20010 USA
- />The George Washington University, Washington DC, USA
| | | | | |
Collapse
|
22
|
De Schacht C, Hoffman HJ, Mabunda N, Lucas C, Alons CL, Madonela A, Vubil A, Ferreira OC, Calú N, Santos IS, Jani IV, Guay L. High rates of HIV seroconversion in pregnant women and low reported levels of HIV testing among male partners in Southern Mozambique: results from a mixed methods study. PLoS One 2014; 9:e115014. [PMID: 25542035 PMCID: PMC4277288 DOI: 10.1371/journal.pone.0115014] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Accepted: 11/17/2014] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION Prevention of acute HIV infections in pregnancy is required to achieve elimination of pediatric HIV. Identification and support for HIV negative pregnant women and their partners, particularly serodiscordant couples, are critical. A mixed method study done in Southern Mozambique estimated HIV incidence during pregnancy, associated risk factors and factors influencing partner's HIV testing. METHODS Between April 2008 and November 2011, a prospective cohort of 1230 HIV negative pregnant women was followed during pregnancy. A structured questionnaire, HIV testing, and collection of dried blood spots were done at 2-3 scheduled visits. HIV incidence rates were calculated by repeat HIV testing and risk factors assessed by Poisson regression. A qualitative study including 37 individual interviews with men, women, and nurses and 11 focus group discussions (n = 94) with men, women and grandmothers explored motivators and barriers to uptake of male HIV testing. RESULTS HIV incidence rate was estimated at 4.28/100 women-years (95%CI: 2.33-7.16). Significant risk factors for HIV acquisition were early sexual debut (RR 3.79, 95%CI: 1.04-13.78, p = 0.04) and living in Maputo Province (RR 4.35, 95%CI: 0.97-19.45, p = 0.05). Nineteen percent of women reported that their partner had tested for HIV (93% knew the result with 8/213 indicating an HIV positive partner), 56% said their partner had not tested and 19% did not know their partner test status. Of the 14 seroconversions, only one reported being in a serodiscordant relationship. Fear of discrimination or stigma was reported as a key barrier to male HIV testing, while knowing the importance of getting tested and receiving care was the main motivator. CONCLUSIONS HIV incidence during pregnancy is high in Southern Mozambique, but knowledge of partners' HIV status remains low. Knowledge of both partners' HIV status is critical for maximal effectiveness of prevention and treatment services to reach elimination of pediatric HIV/AIDS.
Collapse
Affiliation(s)
- Caroline De Schacht
- Elizabeth Glaser Pediatric AIDS Foundation, Research Department, Maputo, Mozambique
- * E-mail:
| | - Heather J. Hoffman
- The George Washington University, Milken Institute School of Public Health, Department of Epidemiology and Biostatistics, Washington, D.C., United States of America
| | | | - Carlota Lucas
- Elizabeth Glaser Pediatric AIDS Foundation, Research Department, Maputo, Mozambique
| | - Catharina L. Alons
- Elizabeth Glaser Pediatric AIDS Foundation, Research Department, Maputo, Mozambique
- Elizabeth Glaser Pediatric AIDS Foundation, Research Department, Washington, D.C., United States of America
| | - Ana Madonela
- Elizabeth Glaser Pediatric AIDS Foundation, Research Department, Maputo, Mozambique
| | | | - Orlando C. Ferreira
- Federal University of Rio de Janeiro, Biology Institute, Rio de Janeiro, Brazil
| | | | | | | | - Laura Guay
- The George Washington University, Milken Institute School of Public Health, Department of Epidemiology and Biostatistics, Washington, D.C., United States of America
- Elizabeth Glaser Pediatric AIDS Foundation, Research Department, Washington, D.C., United States of America
| |
Collapse
|
23
|
Stalgaitis CA, Rath JM, Williams V, Hoffman HJ. Association between financial dependence and tobacco use among young adults. Am J Health Behav 2014; 38:850-9. [PMID: 25207511 DOI: 10.5993/ajhb.38.6.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVES To evaluate the relationship between financial dependence on parents and young adult tobacco use. METHODS Cross-sectional data (N = 4195) were analyzed. Multinomial and binary logistic regression were used to model financial dependence as a predictor of tobacco use and frequency of use. RESULTS Most participants were financially independent (53.5%) and current (27.3%) or previous (26.8%) users. Income, education, and employment interacted with financial dependence to predict tobacco use. Dependent participants had greater odds of current (OR range: 3.28-7.17) and lower odds of previous use (0.14-0.37) than independent participants. Financial dependence did not predict frequency of current use. CONCLUSIONS Greater financial dependence on parents is associated with increased current and decreased previous tobacco use among young adults.
Collapse
Affiliation(s)
| | | | | | - Heather J Hoffman
- Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA
| |
Collapse
|
24
|
Zhou CK, Pfeiffer RM, Cleary SD, Hoffman HJ, Levine PH, Chu LW, Hsing AW, Cook MB. Abstract 3260: Male pattern baldness increases the risk of aggressive prostate cancer: A prospective analysis of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-3260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Androgenic actions are thought to underlie the development of both male pattern baldness and prostate cancer. However, results from previous studies of the relationship between these two phenotypes have been inconsistent. Therefore, we investigated the association of male pattern baldness at age 45 years with overall and aggressive prostate cancer risk in a large, prospective cohort–the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Methods: We included 39,070 men, from the usual care and screening arms of the trial, who were cancer-free at start of follow-up. Hazard ratios (HRs) and 95% confidence intervals (95%CIs) were estimated using Cox proportional hazards regression models with age as the underlying time-scale.
Results: During follow-up (median=2.78 years), 1,138 incident prostate cancer cases were diagnosed, 578 of which were aggressive (Gleason score ≥ 7, stage ≥ III, or fatal). Frontal + vertex balding at age 45 years, compared with no balding, was not associated with overall prostate cancer risk (HR=1.19, 95%CI: 0.98, 1.45), but was associated with increased risk of aggressive prostate cancer (HR=1.42, 95%CI: 1.10, 1.83). Adjustment for covariates did not significantly alter these estimates. Other classes of male pattern baldness were not associated with the overall or aggressive prostate cancer.
Conclusion: Our analysis indicates that frontal + vertex balding at age 45 years increases the risk for future development of aggressive prostate cancer, and supports the possibility of overlapping pathogenesis.
Citation Format: Cindy Ke Zhou, Ruth M. Pfeiffer, Sean D. Cleary, Heather J. Hoffman, Paul H. Levine, Lisa W. Chu, Ann W. Hsing, Michael B. Cook. Male pattern baldness increases the risk of aggressive prostate cancer: A prospective analysis of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3260. doi:10.1158/1538-7445.AM2014-3260
Collapse
Affiliation(s)
- Cindy K. Zhou
- 1George Washington University; National Cancer Institute, Bethesda, MD
| | | | | | | | | | - Lisa W. Chu
- 4Cancer Prevention Institute of California, Fremont, CA
| | - Ann W. Hsing
- 4Cancer Prevention Institute of California, Fremont, CA
| | | |
Collapse
|
25
|
Zhou CK, Pfeiffer RM, Cleary SD, Hoffman HJ, Levine PH, Chu LW, Hsing AW, Cook MB. Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. J Clin Oncol 2014; 33:419-25. [PMID: 25225425 DOI: 10.1200/jco.2014.55.4279] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
PURPOSE Male pattern baldness and prostate cancer appear to share common pathophysiologic mechanisms. However, results from previous studies that assess their relationship have been inconsistent. Therefore, we investigated the association of male pattern baldness at age 45 years with risks of overall and subtypes of prostate cancer in a large, prospective cohort—the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. METHODS We included 39,070 men from the usual care and screening arms of the trial cohort who had no cancer diagnosis (excluding nonmelanoma skin cancer) at the start of follow-up and recalled their hair-loss patterns at age 45 years. Hazard ratios (HRs) and 95% CIs were estimated by using Cox proportional hazards regression models with age as the time metric. RESULTS During follow-up (median, 2.78 years), 1,138 incident prostate cancer cases were diagnosed, 571 of which were aggressive (biopsy Gleason score ≥ 7, and/or clinical stage III or greater, and/or fatal). Compared with no baldness, frontal plus moderate vertex baldness at age 45 years was not significantly associated with overall (HR, 1.19; 95% CI, 0.98 to 1.45) or nonaggressive (HR, 0.97; 95% CI, 0.72 to 1.30) prostate cancer risk but was significantly associated with increased risk of aggressive prostate cancer (HR, 1.39; 95% CI, 1.07 to 1.80). Adjustment for covariates did not substantially alter these estimates. Other classes of baldness were not significantly associated with overall or subtypes of prostate cancer. CONCLUSION Our analysis indicates that frontal plus moderate vertex baldness at age 45 years is associated with an increased risk of aggressive prostate cancer and supports the possibility of common pathophysiologic mechanisms.
Collapse
Affiliation(s)
- Cindy Ke Zhou
- Cindy Ke Zhou, Ruth M. Pfeiffer, and Michael B. Cook, National Cancer Institute, Bethesda, MD; Cindy Ke Zhou, Sean D. Cleary, Heather J. Hoffman, and Paul H. Levine, George Washington University, Washington, DC; and Lisa W. Chu and Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA
| | - Ruth M Pfeiffer
- Cindy Ke Zhou, Ruth M. Pfeiffer, and Michael B. Cook, National Cancer Institute, Bethesda, MD; Cindy Ke Zhou, Sean D. Cleary, Heather J. Hoffman, and Paul H. Levine, George Washington University, Washington, DC; and Lisa W. Chu and Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA
| | - Sean D Cleary
- Cindy Ke Zhou, Ruth M. Pfeiffer, and Michael B. Cook, National Cancer Institute, Bethesda, MD; Cindy Ke Zhou, Sean D. Cleary, Heather J. Hoffman, and Paul H. Levine, George Washington University, Washington, DC; and Lisa W. Chu and Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA
| | - Heather J Hoffman
- Cindy Ke Zhou, Ruth M. Pfeiffer, and Michael B. Cook, National Cancer Institute, Bethesda, MD; Cindy Ke Zhou, Sean D. Cleary, Heather J. Hoffman, and Paul H. Levine, George Washington University, Washington, DC; and Lisa W. Chu and Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA
| | - Paul H Levine
- Cindy Ke Zhou, Ruth M. Pfeiffer, and Michael B. Cook, National Cancer Institute, Bethesda, MD; Cindy Ke Zhou, Sean D. Cleary, Heather J. Hoffman, and Paul H. Levine, George Washington University, Washington, DC; and Lisa W. Chu and Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA
| | - Lisa W Chu
- Cindy Ke Zhou, Ruth M. Pfeiffer, and Michael B. Cook, National Cancer Institute, Bethesda, MD; Cindy Ke Zhou, Sean D. Cleary, Heather J. Hoffman, and Paul H. Levine, George Washington University, Washington, DC; and Lisa W. Chu and Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA
| | - Ann W Hsing
- Cindy Ke Zhou, Ruth M. Pfeiffer, and Michael B. Cook, National Cancer Institute, Bethesda, MD; Cindy Ke Zhou, Sean D. Cleary, Heather J. Hoffman, and Paul H. Levine, George Washington University, Washington, DC; and Lisa W. Chu and Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA
| | - Michael B Cook
- Cindy Ke Zhou, Ruth M. Pfeiffer, and Michael B. Cook, National Cancer Institute, Bethesda, MD; Cindy Ke Zhou, Sean D. Cleary, Heather J. Hoffman, and Paul H. Levine, George Washington University, Washington, DC; and Lisa W. Chu and Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA.
| |
Collapse
|
26
|
De Schacht C, Mabunda N, Ferreira OC, Ismael N, Calú N, Santos I, Hoffman HJ, Alons C, Guay L, Jani IV. High HIV incidence in the postpartum period sustains vertical transmission in settings with generalized epidemics: a cohort study in Southern Mozambique. J Int AIDS Soc 2014; 17:18808. [PMID: 24629842 PMCID: PMC3946505 DOI: 10.7448/ias.17.1.18808] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2013] [Revised: 12/14/2013] [Accepted: 01/17/2014] [Indexed: 11/08/2022] Open
Abstract
INTRODUCTION Acute infection with HIV in the postpartum period results in a high risk of vertical transmission through breastfeeding. A study was done to determine the HIV incidence rate and associated risk factors among postpartum women in Southern Mozambique, where HIV prevalence among pregnant women is 21%. METHODS A prospective cohort study was conducted in six rural health facilities in Gaza and Maputo provinces from March 2008 to July 2011. A total of 1221 women who were HIV-negative on testing at delivery or within two months postpartum were recruited and followed until 18 months postpartum. HIV testing, collection of dried blood spot samples and administration of a structured questionnaire to women were performed every three months. Infant testing by DNA-PCR was done as soon as possible after identification of a new infection in women. HIV incidence was estimated, and potential risk factors at baseline were compared using Poisson regression. RESULTS Data from 957 women were analyzed with follow-up after the enrolment visit, with a median follow-up of 18.2 months. The HIV incidence in postpartum women is estimated at 3.20/100 women-years (95% CI: 2.30-4.46), with the highest rate among 18- to 19-year-olds (4.92 per 100 women-years; 95% CI: 2.65-9.15). Of the new infections, 14 (34%) were identified during the first six months postpartum, 11 (27%) between 6 and 12 months and 16 (39%) between 12 and 18 months postpartum. Risk factors for incident HIV infection include young age, low number of children, higher education level of the woman's partner and having had sex with someone other than one's partner. The vertical transmission was 21% (95% CI: 5-36) among newly infected women. CONCLUSIONS Incidence of HIV is high among breastfeeding women in Southern Mozambique, contributing to increasing numbers of HIV-infected infants. Comprehensive primary prevention strategies targeting women of reproductive age, particularly pregnant and postpartum women and their partners, will be crucial for the elimination of paediatric AIDS in Africa.
Collapse
Affiliation(s)
| | - Nédio Mabunda
- Instituto Nacional de Saúde, Ministry of Health, Maputo, Mozambique
| | - Orlando C Ferreira
- Biology Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Nália Ismael
- Instituto Nacional de Saúde, Ministry of Health, Maputo, Mozambique
| | - Nurbai Calú
- Provincial Health Directorate Gaza, Xai-Xai, Mozambique
| | - Iolanda Santos
- Provincial Health Directorate Maputo, Matola, Mozambique
| | - Heather J Hoffman
- Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington DC, USA
| | - Catharina Alons
- Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique
| | - Laura Guay
- Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique; Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington DC, USA
| | - Ilesh V Jani
- Instituto Nacional de Saúde, Ministry of Health, Maputo, Mozambique
| |
Collapse
|
27
|
Levine PH, Hoffman HJ, MacNeil A, Hashmi S, Yang SX, Hewitt S, Golen KLV, Swain SM. Prognostic Value of Lymphocyte Vascular Density and E-Cadherin in Inflammatory Breast Cancer. ACTA ACUST UNITED AC 2014. [DOI: 10.4236/jct.2014.514139] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
28
|
Gibb H, Fulcher K, Nagarajan S, McComish S, Fallahian NA, Hoffman HJ, Haver C, Tolmachev S. Gibb et al. respond. Am J Public Health 2013; 104:e1-2. [PMID: 24328624 DOI: 10.2105/ajph.2013.301760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- Herman Gibb
- Herman Gibb and Keri Fulcher are with Tetra Tech Sciences, Arlington, VA. Sumitha Nagarajan is with the American Registry of Pathology, Dover, DE. Stacey McComish and Sergei Tolmachev are with the US Transuranium and Uranium Registries, College of Pharmacy, Washington State University, Richland. Naz Afarin Fallahian is with the Department of Physics and Engineering Technology, Bloomsburg University of Pennsylvania, Bloomsburg. Heather J. Hoffman is with the Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington, DC. At the time of the study, Cary Haver was with Tetra Tech Sciences
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Jhaveri K, Teplinsky E, Arzu R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Silvera D, Levine PH, Hashmi S, Hoffman HJ, Paul L, Singh B, Goldberg JD, Hochman T, Formenti S, Valeta A, Moran MS, Schneider RJ. Abstract PD5-6: Sustained hyperactivated mTOR & JAK2/STAT3 pathways in inflammatory breast cancer (IBC): Evidence for mTOR plus JAK2 therapeutic targeting. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd5-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: IBC is an aggressive form of breast cancer with poor prognosis. Combined multi-modality therapy results in a 5 year OS of 30%, underscoring the unmet need for targeted therapy. Our preclinical research in cell lines & xenograft tumor models has identified a role for hyper-activated PI3K/mTOR signaling in IBC. IBC cells express IL-6 and IL-8, which recruit tumor activated macrophages (TAMs) that further induce inflammatory cytokines and activate the JAK2/STAT3 pathway. We investigated the independent and combined activity of these pathways in IBC patient tissues.
Methods: Archived tissue specimens of 42 IBC patients (dx 1999-2009) and 27 non-IBC patients (dx 2001-2005) with invasive ductal carcinoma (IDC) were obtained. Surrounding non-tumor normal tissue from IBC (companion controls) was also utilized. All specimens were analyzed using immunohistochemistry (IHC) and scored by 3 independent pathologists. Results were defined as 0 = negative; 1+,2+ = positive for activated mTOR (P-S6); activated JAK2/STAT3 (P-JAK2; P-STAT3); cytokine (IL-6); macrophage infiltration (CD68) and TAM (CD163). Proportions of IBC cases with positive expression were compared with non-IBC cases (Fisher's exact test) & companion controls (McNemar's test). Clinical & survival data were obtained.
Results: Median age at diagnosis: 46 yrs (31-62) in early stage IBC [EIBC] (n = 37) & 41 yrs (29-57) in pts with de novo metastatic IBC [MIBC] (n = 5). In EIBC, 19/36: HER2+ (1 unk); 8/19: ER+/HER2+; 8/36: ER-/HER2-. In MIBC, all were ER- (1 unk) & 3/4 were HER2+ (1 unk). 88% were rx with neoadjuvant &/or adjuvant anthracycline & taxane w/o adjuvant trastuzumab. There were 24 pt deaths (5/5 MIBC). Median f/u for EIBC: 6.3 yrs and for MIBC: 3.4 yrs. Median OS: 81.4 mo (95% CI lower 48 mo) for EIBC & 41 mo (95% CI 8-81 mo) for MIBC. Median RFS: 18 mo (95% CI 18-79 mo) for 23 pts (13 NED; 1 unk). The non-IBC patients were all stage 2-3 with median age at diagnosis: 58 yrs (39-94). 19/27: ER+; 7/25 HER2+ (2 unk); 15/25 ER+/HER2-; 3/25 ER-/HER2-. 78% were rx with adjuvant anthracycline & taxane, 4% were rx with FEC and 18% did not receive adjuvant chemotherapy. 18% received adjuvant trastuzumab. Median f/u: 8.0 yrs. Median OS: not yet reached and median RFS: 111.3 mo (95% CI lower 34.5 mo). EIBC cases were compared with non-IBC cases & companion controls (Table 1). PS6, pJAK2 and pSTAT3 expression was significantly increased in IBC compared to non-IBC. Of the 29 EIBC patients with complete biomarker data who were PS6+, 28/29 (97%) were JAK2+, 15/29 (52%) were STAT3+, 26/29 (90%) were CD68+, 20/29 (69%) were CD163+ and 28/29 (97%) were IL6+.
Conclusion: This is the first study to validate preclinical findings & show a strong co-association between hyper-activation of mTOR & JAK/STAT pathways in most IBC patient tumors when compared to surrounding non-tumor tissue and non-IBC (IDC) tumors and tissues. These findings suggest a key role for dual blockade of mTOR & JAK/STAT pathways for IBC in phase I trials.
BiomarkerMcNemars p-value: Early Stage IBC vs companion controls (N = 37)Fishers p-value: Early stage IBC (N = 37)vs non-IBC (N = 27)PS6<0.00010.0315pJAK2<0.0001<0.0001pSTAT30.0003<0.0001CD163<0.00010.0908CD68<0.00010.0582IL60.00030.3882
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD5-6.
Collapse
Affiliation(s)
- K Jhaveri
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - E Teplinsky
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - R Arzu
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - S Giashuddin
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - Y Sarfraz
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - M Alexander
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - F Darvishian
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - D Silvera
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - PH Levine
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - S Hashmi
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - HJ Hoffman
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - L Paul
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - B Singh
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - JD Goldberg
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - T Hochman
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - S Formenti
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - A Valeta
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - MS Moran
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| | - RJ Schneider
- New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine
| |
Collapse
|
30
|
Davis NJ, Ma Y, Delahanty LM, Hoffman HJ, Mayer-Davis E, Franks PW, Brown-Friday J, Isonaga M, Kriska AM, Venditti EM, Wylie-Rosett J. Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. J Acad Nutr Diet 2013; 113:1455-1464. [PMID: 24144073 DOI: 10.1016/j.jand.2013.07.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2013] [Accepted: 06/23/2013] [Indexed: 10/26/2022]
Abstract
BACKGROUND Few lifestyle intervention studies examine long-term sustainability of dietary changes. OBJECTIVE To describe sustainability of dietary changes over 9 years in the Diabetes Prevention Program and its outcomes study, the Diabetes Prevention Program Outcomes Study, among participants receiving the intensive lifestyle intervention. DESIGN One thousand seventy-nine participants were enrolled in the intensive lifestyle intervention arm of the Diabetes Prevention Program; 910 continued participation in the Diabetes Prevention Program Outcomes Study. Fat and energy intake derived from food frequency questionnaires at baseline and post-randomization Years 1 and 9 were examined. Parsimonious models determined whether baseline characteristics and intensive lifestyle intervention session participation predicted sustainability. RESULTS Self-reported energy intake was reduced from a median of 1,876 kcal/day (interquartile range [IQR]=1,452 to 2,549 kcal/day) at baseline to 1,520 kcal/day (IQR=1,192 to 1,986 kcal/day) at Year 1, and 1,560 kcal/day (IQR=1,223 to 2,026 kcal/day) at Year 9. Dietary fat was reduced from a median of 70.4 g (IQR=49.3 to 102.5 g) to 45 g (IQR=32.2 to 63.8 g) at Year 1 and increased to 61.0 g (IQR=44.6 to 82.7 g) at Year 9. Percent energy from fat was reduced from a median of 34.4% (IQR=29.6% to 38.5%) to 27.1% (IQR=23.1% to 31.5%) at Year 1 but increased to 35.3% (IQR=29.7% to 40.2%) at Year 9. Lower baseline energy intake and Year 1 dietary reduction predicted lower energy and fat gram intake at Year 9. Higher leisure physical activity predicted lower fat gram intake but not energy intake. CONCLUSIONS Intensive lifestyle intervention can result in reductions in total energy intake for up to 9 years. Initial success in achieving reductions in fat and energy intake and success in attaining activity goals appear to predict long-term success at maintaining changes.
Collapse
|
31
|
Abstract
Through Value Enhanced Nutrition Assessment and other techniques, the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) engages clients to set their own nutrition goals. A case series of 30 Hispanic children (2-4.5 years) at ≥85th body mass index (BMI) percentile and their caregivers were followed through an urban WIC clinic. The dyads received either standard counseling ( n = 15) or motivational interviewing (MI; n = 15) by one bilingual WIC nutritionist during 4 regularly scheduled visits over 6 months. Repeated measurements of anthropometric data, dietary patterns, and physical activity were obtained at each visit. Longitudinal bivariate analyses of caregiver concerns and goal selection were conducted along with mean comparisons of anthropometric and food frequency measures. Participation in counseling sessions as rated by the nutritionist was assessed by comparing Wilcoxon rank-sum scores. After counseling, children lost an adjusted mean weight of 0.878 kg (95% confidence interval = 0.280-1.717). A decline in median BMI of more than 3 percentiles ( P = .042) was observed with both counseling approaches. Caregiver-reported vegetable intake of children increased an average of one additional serving in the MI-counseled group by visit 3 ( P = .013) despite MI recipient caregivers being scored as significantly more distracted than standard WIC participants in the first visit ( P = .036). MI is a viable option for WIC counseling to improve diet and health outcomes in participants, particularly in addressing child BMI status and vegetable intake. Public health professionals should examine scalability of the MI approach among larger samples of WIC participants and other innovative techniques to improve client focus during counseling.
Collapse
Affiliation(s)
- Linda C. Ogu
- Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington, DC (LCO, HJH)
- Children’s National Medical Center, Washington, DC (JJ, LM, ERM)
- University of Maryland, College Park, Maryland (APV)
- LSRO Solutions, Bethesda, Maryland (CJK)
| | - Jayasri Janakiram
- Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington, DC (LCO, HJH)
- Children’s National Medical Center, Washington, DC (JJ, LM, ERM)
- University of Maryland, College Park, Maryland (APV)
- LSRO Solutions, Bethesda, Maryland (CJK)
| | - Heather J. Hoffman
- Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington, DC (LCO, HJH)
- Children’s National Medical Center, Washington, DC (JJ, LM, ERM)
- University of Maryland, College Park, Maryland (APV)
- LSRO Solutions, Bethesda, Maryland (CJK)
| | - Libia McDonough
- Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington, DC (LCO, HJH)
- Children’s National Medical Center, Washington, DC (JJ, LM, ERM)
- University of Maryland, College Park, Maryland (APV)
- LSRO Solutions, Bethesda, Maryland (CJK)
| | - Ana P. Valencia
- Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington, DC (LCO, HJH)
- Children’s National Medical Center, Washington, DC (JJ, LM, ERM)
- University of Maryland, College Park, Maryland (APV)
- LSRO Solutions, Bethesda, Maryland (CJK)
| | - Eleanor R. Mackey
- Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington, DC (LCO, HJH)
- Children’s National Medical Center, Washington, DC (JJ, LM, ERM)
- University of Maryland, College Park, Maryland (APV)
- LSRO Solutions, Bethesda, Maryland (CJK)
| | - Catherine J. Klein
- Department of Epidemiology and Biostatistics, School of Public Health and Health Services, The George Washington University, Washington, DC (LCO, HJH)
- Children’s National Medical Center, Washington, DC (JJ, LM, ERM)
- University of Maryland, College Park, Maryland (APV)
- LSRO Solutions, Bethesda, Maryland (CJK)
| |
Collapse
|
32
|
Teplinsky E, Valeta A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Silvera D, Levine PH, Hashmi S, Paul L, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Formenti S, Schneider R, Jhaveri KL. Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.26_suppl.60] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
60 Background: IBC is an aggressive form of breast cancer with poor prognosis. Combined multi-modality Rx results in a 5 year OS of 30-50%, underscoring the unmet need for targeted Rx. Our preclinical research in cell lines and xenografts identifies a role for activated PI3K/mTOR pathway in IBC. IBC cells express IL-6 and IL-8 and recruit tumor activated macrophages (TAMs) that further induce IL-6, IL-8 and activate the JAK2/STAT3 pathway. We investigated the independent and combined activity of these pathways in IBC tissues. Methods: Archived tissues of 42 IBC pts and 13 controls (nl breast) were analyzed using IHC and scored by 3 independent pathologists. Results defined as: 0, 1+ = neg; 2+ = pos for activated mTOR (P-S6) and 0 = neg; 1+, 2+ = pos for activated nuclear JAK2/STAT3 (P-JAK2; P-STAT3), cytokine (IL-6), macrophage (mØ) infiltration (CD68) and TAM (CD163). Proportions of IBC cases with pos expression were compared with controls (Fishers exact tests). Clinical and survival data were obtained. Results: Median age at diagnosis: 46 yrs (31-62) in early-stage IBC [EIBC] (n=37) and 41 yrs (29-57) in pts with de novo metastatic IBC [MIBC] (n=5). In EIBC, 19/36: HER2+ (1 unk); 8/19: ER+/HER2+; 8/36: ER-/HER2-. In MIBC, all were ER- (1 unk) and 3/4 were HER2+ (1 unk). 88% Rx with neoadjuvant and/or adjuvant anthracycline and taxane w/o adjuvant trastuzumab. 24 pts died (5/5 MIBC). Median OS: 86 mo (95% CI lower 48 mo) for EIBC & 41 mo (95% CI 8-81 mo) for MIBC. Median RFS: 18 mo (95% CI 18-79 mo) for 23 pts (13 NED; 1 unk). All controls: neg for P-S6, JAK2, STAT3 and TAMs and 92% neg for mØ and IL-6. Proportion of IBC with pos expression when compared to controls listed in table (p <0.0001). Of 31 pts with complete biomarker data who were PS6+, 97% had activated JAK2, 58% had activated STAT3, 80% had strong mØ and TAM infiltration and 97% were IL6+. Conclusions: This is the first study that validates preclinical findings and shows a strong association between mTOR, cytokines, TAMs and JAK/STAT pathways in most IBC pt tissues. Findings suggest a key role for dual blockade of mTOR and JAK/STAT pathways in phase I trials. [Table: see text]
Collapse
Affiliation(s)
| | - Amanda Valeta
- New York University School of Medicine, New York, NY
| | - Rezina Arju
- New York University School of Medicine, New York, NY
| | | | | | | | - Farbod Darvishian
- Department of Pathology, New York University School of Medicine, New York, NY
| | | | - Paul H. Levine
- Department of Epidemiology and Biostatistics, George Washington University, Washington, DC
| | - Salman Hashmi
- The George Washington University, School of Public Health and Health Services, Washington, DC
| | - Ladan Paul
- Department of Epidemiology and Biostatistics, George Washington University, Washington, DC
| | | | - Baljit Singh
- New York University Langone Medical Center, New York, NY
| | | | | | | | | | | |
Collapse
|
33
|
Plankey MW, Hoffman HJ, Springer G, Cox C, Young MA, Margolick JB, Torre P. P2.119 The Prevalence of Hearing Sensitivity Among HIV-Seropositive and HIV-Seronegative Men and Women. Br J Vener Dis 2013. [DOI: 10.1136/sextrans-2013-051184.0383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Jhaveri KL, Teplinsky E, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Silvera D, Levine PH, Hashmi S, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Valeta A, Schneider R. Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.11106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11106 Background: IBC is an aggressive form of breast cancer with poor prognosis. Combined multimodality Rx results in 5 year median OS of 30-50%, underscoring the unmet need for novel targeted strategies. Our preclinical research in cell lines and xenografts suggests a role for activated PI3K/AKT/mTOR pathway in IBC. IBC cells not only express high levels of IL-6 and IL-8 but can recruit tumor activated macrophages (TAMs), which can further induce IL-6, IL-8 and activate JAK2/STAT3 pathway. We therefore investigated independent and combined activity of these pathways. Methods: Archived tissue specimens of 42 IBC pts (1999 - 2009) and 13 controls (normal breast) were analyzed using IHC and scored by 3 independent pathologists. Results were defined as: 0, 1+ = neg; 2+ = pos for activated mTOR (phosphorylatedS6) and 0 = neg; 1+, 2+ = pos for activated nuclear JAK2/STAT3 (pJAK2; pSTAT3), cytokine (IL-6), macrophage infiltration (CD68) and TAMs (CD163). Proportion of IBC cases with pos expression were compared to proportion among controls (Fishers exact test). Clinical and survival data were obtained. Results: Median age at diagnosis - 44.5 yrs (29-64). 22 had HER2 overexpression (8 also ER+) and 9 were ER-/HER2-; ER & HER2 unknown for 1 and 2 pts respectively. Majority were Rxed with neoadjuvant anthracycline and/taxane without adjuvant trastuzumab. There were 24 deaths. Median OS: 67 mths (95% CI: lower 41). Proportions of IBC cases with pos expression when compared to controls are listed in the table (Fishers p value: <0.0001). Of the 31 pts with complete biomarker data who were PS6 pos, 97% had activated JAK2 & 58% had activated STAT3 (McNemar’s chi square, p <0.001). 24/31 (80%) showed strong infiltration of macrophages and TAMs. All cases had widespread IL6 staining. Conclusions: This study validates our preclinical findings and shows hyperactivation of mTOR and JAK2 signaling in vast majority of IBC specimens, with close association between mTOR, TAMs, cytokines and JAK2/STAT3 pathways. These findings support a role for dual blockade of mTOR and JAK/STAT pathways in clinical trials. [Table: see text]
Collapse
Affiliation(s)
| | | | - Rezina Arju
- New York University School of Medicine, New York, NY
| | | | | | | | - Farbod Darvishian
- Department of Pathology, New York University School of Medicine, New York, NY
| | | | - Paul H Levine
- Department of Epidemiology and Biostatistics, George Washington University, Washington, DC
| | - Salman Hashmi
- The George Washington University, School of Public Health and Health Services, Washington, DC
| | | | - Baljit Singh
- New York University Langone Medical Center, New York, NY
| | | | | | - Amanda Valeta
- New York University School of Medicine, New York, NY
| | | |
Collapse
|
35
|
Gibb H, Fulcher K, Nagarajan S, McCord S, Fallahian NA, Hoffman HJ, Haver C, Tolmachev S. Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries. Am J Public Health 2013; 103:710-6. [PMID: 23409888 PMCID: PMC3673239 DOI: 10.2105/ajph.2012.300928] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2012] [Indexed: 11/04/2022]
Abstract
OBJECTIVES We examined the relationship between radiation and excess deaths from mesothelioma among deceased nuclear workers who were part of the US Transuranium and Uranium Registries. METHODS We performed univariate analysis with SAS Version 9.1 software. We conducted proportionate mortality ratio (PMR) and proportionate cancer mortality ratio (PCMR) analyses using the National Institute for Occupational Safety and Health Life Table Analysis System with the referent group being all deaths in the United States. RESULTS We found a PMR of 62.40 (P < .05) and a PCMR of 46.92 (P < .05) for mesothelioma. PMRs for the 4 cumulative external radiation dose quartiles were 61.83, 57.43, 74.46, and 83.31. PCMRs were 36.16, 47.07, 51.35, and 67.73. The PMR and PCMR for trachea, bronchus, and lung cancer were not significantly elevated. CONCLUSIONS The relationship between cumulative external radiation dose and the PMR and PCMR for mesothelioma suggests that external radiation at nuclear facilities is associated with an increased risk of mesothelioma. The lack of a significantly elevated PMR and PCMR for trachea, bronchus, and lung cancer suggests that asbestos did not confound this relationship.
Collapse
Affiliation(s)
- Herman Gibb
- Tetra Tech Sciences, Arlington, VA 22201, USA.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Gale HB, Rodriguez MD, Hoffman HJ, Benator DA, Gordin FM, Labriola AM, Kan VL. Progress realized: trends in HIV-1 viral load and CD4 cell count in a tertiary-care center from 1999 through 2011. PLoS One 2013; 8:e56845. [PMID: 23437255 PMCID: PMC3577700 DOI: 10.1371/journal.pone.0056845] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2012] [Accepted: 01/15/2013] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND HIV-1 RNA and CD4 cell counts are important parameters for HIV care. The objective of this study was to assess the overall trends in HIV-1 viral load and CD4 cell counts within our clinic. METHODS Patients with at least one of each test performed by the Infectious Diseases Laboratory from 1999 through 2011 were included in this analysis. By adapting a novel statistical model, log(10) HIV-1 RNA means were estimated by month, and log(10)-transformed HIV-1 RNA means were estimated by calendar year. Geometric means were calculated for CD4 cell counts by month and calendar year. Log(10) HIV-1 RNA and CD4 cell count monthly means were also examined with polynomial regression. RESULTS There were 1,814 individuals with approximately 25,000 paired tests over the 13-year observation period. Based on each patient's final value of the year, the percentage of patients with viral loads below the lower limit of quantitation rose from 29% in 1999 to 72% in 2011, while the percentage with CD4 counts <200 cells/µL fell from 31% to 11%. On average annually, the mean HIV-1 RNA decreased by 86 copies/mL and the mean CD4 counts increased by 16 cells/µL. For the monthly means, the correlations (R(2)) from second-order polynomial regressions were 0.944 for log(10) HIV-1 RNA and 0.840 for CD4 cell counts. CONCLUSIONS Marked improvements in HIV-1 RNA suppression and CD4 cell counts were achieved in a large inner-city population from 1999 through 2011. This success demonstrates that sustained viral control with improved immunologic status can be a realistic goal for most individuals in clinical care.
Collapse
Affiliation(s)
- Howard B Gale
- Infectious Diseases Section, Medical Service, Veterans Affairs Medical Center, Washington, DC, USA.
| | | | | | | | | | | | | |
Collapse
|
37
|
Gale HB, Gitterman SR, Hoffman HJ, Gordin FM, Benator DA, Labriola AM, Kan VL. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression? Clin Infect Dis 2013; 56:1340-3. [PMID: 23315315 DOI: 10.1093/cid/cit004] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Among patients infected with human immunodeficiency virus (HIV), those with HIV-1 RNA <200 copies/mL and CD4 counts ≥300 cells/µL had a 97.1% probability of maintaining durable CD4 ≥200 cells/µL for 4 years. When non-HIV causes of CD4 lymphopenia were excluded, the probability rose to 99.2%. Our data support less frequent CD4 monitoring during viral suppression.
Collapse
Affiliation(s)
- Howard B Gale
- Infectious Diseases Section, Medical Service, Veterans Affairs Medical Center, 50 Irving St NW, Washington, DC 20422, USA.
| | | | | | | | | | | | | |
Collapse
|
38
|
Hoffman HJ, LaVerda NL, Young HA, Levine PH, Alexander LM, Brem R, Caicedo L, Eng-Wong J, Frederick W, Funderburk W, Huerta E, Swain S, Patierno SR. Patient navigation significantly reduces delays in breast cancer diagnosis in the District of Columbia. Cancer Epidemiol Biomarkers Prev 2012; 21:1655-63. [PMID: 23045540 DOI: 10.1158/1055-9965.epi-12-0479] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Patient Navigation (PN) originated in Harlem as an intervention to help poor women overcome access barriers to timely breast cancer treatment. Despite rapid, nationally widespread adoption of PN, empirical evidence on its effectiveness is lacking. In 2005, National Cancer Institute initiated a multicenter PN Research Program (PNRP) to measure PN effectiveness for several cancers. The George Washington Cancer Institute, a project participant, established District of Columbia (DC)-PNRP to determine PN's ability to reduce breast cancer diagnostic time (number of days from abnormal screening to definitive diagnosis). METHODS A total of 2,601 women (1,047 navigated; 1,554 concurrent records-based nonnavigated) were examined for breast cancer from 2006 to 2010 at 9 hospitals/clinics in DC. Analyses included only women who reached complete diagnostic resolution. Differences in diagnostic time between navigation groups were tested with ANOVA models including categorical demographic and treatment variables. Log transformations normalized diagnostic time. Geometric means were estimated and compared using Tukey-Kramer P value adjustments. RESULTS Average-geometric mean [95% confidence interval (CI)]-diagnostic time (days) was significantly shorter for navigated, 25.1 (21.7, 29.0), than nonnavigated women, 42.1 (35.8, 49.6). Subanalyses revealed significantly shorter average diagnostic time for biopsied navigated women, 26.6 (21.8, 32.5) than biopsied nonnavigated women, 57.5 (46.3, 71.5). Among nonbiopsied women, diagnostic time was shorter for navigated, 27.2 (22.8, 32.4), than nonnavigated women, 34.9 (29.2, 41.7), but not statistically significant. CONCLUSIONS Navigated women, especially those requiring biopsy, reached their diagnostic resolution significantly faster than nonnavigated women. IMPACT Results support previous findings of PN's positive influence on health care. PN should be a reimbursable expense to assure continuation of PN programs.
Collapse
Affiliation(s)
- Heather J Hoffman
- Department of Epidemiology and Biostatistics, The George Washington University School of Public Health and Health Services, 2100-W Pennsylvania Avenue, NW, 8th Floor, Washington, DC 20037, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Macdonald RL, Hoffman HJ. Subarachnoid hemorrhage and vasospasm following removal of craniopharyngioma. J Clin Neurosci 2012; 4:348-52. [PMID: 18638982 DOI: 10.1016/s0967-5868(97)90104-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/1995] [Accepted: 08/12/1996] [Indexed: 11/24/2022]
Abstract
A patient who had transcranial removal of a craniopharyngioma developed a large, postoperative subarachnoid hematoma in the basal cisterns. The patient developed cerebral vasospasm with infarction. A review of the literature found 20 cases of vasospasm associated with surgical removal of intracranial tumors. These cases were reviewed to determine the role of subarachnoid blood in the causation of vasospasm. In most cases, vasospasm is caused by subarachnoid blood. Multiple causes for arterial narrowing may be present, such as radiation vasculopathy, iatrogenic arterial injury and infection, and may be impossible to exclude as factors contributing to arterial narrowing.
Collapse
Affiliation(s)
- R L Macdonald
- Section of Neurosurgery, University of Chicago, Chicago, Illinois, USA
| | | |
Collapse
|
40
|
Levine PH, Portera CC, Hoffman HJ, Yang SX, Takikita M, Duong QN, Hewitt SM, Swain SM. Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. Clin Breast Cancer 2012; 12:232-9. [PMID: 22694825 DOI: 10.1016/j.clbc.2012.04.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Revised: 03/19/2012] [Accepted: 04/25/2012] [Indexed: 02/08/2023]
Abstract
BACKGROUND Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that on presentation resembles locally advanced breast cancer (LABC). This study identified molecular features of IBC and LABC to investigate pathogenesis. MATERIALS AND METHODS This study involved 100 IBC cases identified in a national IBC registry and 107 non-IBC LABC cases from the National Cancer Institute's Cooperative Breast Cancer Tissue Resource (CBCTR). Vascular endothelial growth factor D (VEGF-D) and E-cadherin levels and lymphatic vessel density (LVD) measured by podoplanin staining were examined by immunohistochemistry on paraffin-embedded tumor specimens. Intralymphatic tumor emboli (ILTE) were assessed in IBC and non-IBC tumors. IBC cases diagnosed by clinicians but not meeting the case definitions of the American Joint Committee on Cancer (AJCC) or the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute (NCI)(designated atypical IBC) were compared with AJCC- and/or SEER-defined cases (designated classic IBC). RESULTS E-cadherin levels were significantly higher in classic IBC cases compared with non-IBC cases (P = .031), whereas compared with classic IBC, patients with non-IBC LABC had significantly higher LVD (P = .0017) and VEGF-D levels (P < .0001). ILTE was marginally greater in classic IBC than in non-IBC (P = .046). The profile of laboratory values in atypical IBC cases more closely resembled those fitting classic IBC than LABC. CONCLUSION E-cadherin levels, LVD, VEGF-D expression, and to a lesser extent, ILTE differed between classic IBC and non-IBC LABC. The similarity of laboratory results between atypical IBC and classic IBC vs. LABC suggests the need for broadening both the AJCC and SEER case definitions for this disease.
Collapse
Affiliation(s)
- Paul H Levine
- George Washington University School of Public Health and Health Services, Washington, DC 20037, USA.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Klein CJ, Villavicencio SA, Schweitzer A, Bethepu JS, Hoffman HJ, Mirza NM. Energy prediction equations are inadequate for obese Hispanic youth. ACTA ACUST UNITED AC 2011; 111:1204-10. [PMID: 21802568 DOI: 10.1016/j.jada.2011.05.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2010] [Accepted: 04/06/2011] [Indexed: 10/17/2022]
Abstract
Assessing energy requirements is a fundamental activity in clinical dietetics practice. A study was designed to determine whether published linear regression equations were accurate for predicting resting energy expenditure (REE) in fasted Hispanic children with obesity (aged 7 to 15 years). REE was measured using indirect calorimetry; body composition was estimated with whole-body air displacement plethysmography. REE was predicted using four equations: Institute of Medicine for healthy-weight children (IOM-HW), IOM for overweight and obese children (IOM-OS), Harris-Benedict, and Schofield. Accuracy of the prediction was calculated as the absolute value of the difference between the measured and predicted REE divided by the measured REE, expressed as a percentage. Predicted values within 85% to 115% of measured were defined as accurate. Participants (n=58; 53% boys) were mean age 11.8±2.1 years, had 43.5%±5.1% body fat, and had a body mass index of 31.5±5.8 (98.6±1.1 body mass index percentile). Measured REE was 2,339±680 kcal/day; predicted REE was 1,815±401 kcal/day (IOM-HW), 1,794±311 kcal/day (IOM-OS), 1,151±300 kcal/day (Harris-Benedict), and, 1,771±316 kcal/day (Schofield). Measured REE adjusted for body weight averaged 32.0±8.4 kcal/kg/day (95% confidence interval 29.8 to 34.2). Published equations predicted REE within 15% accuracy for only 36% to 40% of 58 participants, except for Harris-Benedict, which did not achieve accuracy for any participant. The most frequently accurate values were obtained using IOM-HW, which predicted REE within 15% accuracy for 55% (17/31) of boys. Published equations did not accurately predict REE for youth in the study sample. Further studies are warranted to formulate accurate energy prediction equations for this population.
Collapse
Affiliation(s)
- Catherine J Klein
- Bionutrition Research Program, Children’s National Medical Center, Clinical Research Center, Washington, DC 20010, USA.
| | | | | | | | | | | |
Collapse
|
42
|
Hoffman HJ, LaVerda NL, Levine PH, Young HA, Alexander LM, Patierno SR, Group DCPNRPR. Abstract B90: Patient navigation significantly reduces delays in breast cancer diagnosis in the District of Columbia. Cancer Epidemiol Biomarkers Prev 2011. [DOI: 10.1158/1055-9965.disp-11-b90] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Background: Delays in follow-up after breast cancer screening may contribute to disparities in breast cancer outcomes. To eliminate breast cancer disparities in Washington, D.C., The GW Cancer Institute established the D.C. Citywide Patient Navigation Research Program (DC-PNRP), which is one of nine national PNRP sites funded by the National Cancer Institute and the American Cancer Society to evaluate the effectiveness of patient navigation. The primary objective of this study is to determine the impact of patient navigation in reducing breast cancer diagnostic time, defined as the number of days from abnormal screening to definitive diagnosis.
Methods: This is a prospective study of 1922 women (728 navigated and 1194 concurrent race-matched records-based non-navigated) examined for breast cancer between 1998 and 2010 at nine hospitals and clinics located in Washington, D.C. Analysis of variance (ANOVA) was used to test for significant differences in diagnostic time between navigated and non-navigated women, while controlling for race/ethnicity (non-Hispanic white (NHW), non-Hispanic black (NHB), Hispanic), type of health insurance (private, government, none), and age at abnormal screening (<40, 40–49, 50–59, 60+). Two-way interactions between group and each of the demographic variables race/ethnicity, type of health insurance, and age at abnormal screening were considered. To satisfy model assumptions, diagnostic time was normalized through a log transformation. Geometric means were estimated and compared using a Tukey-Kramer p-value adjustment.
Results: Unadjusted average—geometric mean (95% CI)—diagnostic times (in days) were 23.9 (20.5, 27.8) for navigated and 37.2 (33.0, 41.8) for non-navigated women (p<0.0001). A factorial ANOVA model revealed significant interactions between navigation and both race/ethnicity (p=0.02) and age at abnormal screening (p=0.03) after controlling for type of insurance (p=0.0008). Navigated NHW had a significantly shorter adjusted average diagnostic time, 6.1 (3.5, 10.5) days, than non-navigated NHW, 16.0 (11.5, 22.3) days (p=0.03); and navigated Hispanics had a significantly shorter adjusted average diagnostic time, 26.5 (19.5, 36.0) days, than non-navigated Hispanics, 57.2 (44.8, 73.1) days (p=0.0005). While navigated NHB had a shorter adjusted average diagnostic time, 26.2 (21.5, 31.9) days, than non-navigated NHB, 34.3 (28.4, 41.4) days, this decrease was not statistically significant (p=0.32). Navigation reduced the diagnostic time for women of all ages, but this decrease was statistically significant only for women aged 60+ years (p<0.0001). Navigated women younger than 40 or 60+ had significantly shorter adjusted average diagnostic times than those aged 50–59 (p=0.03 for each). Adjusted average diagnostic times (in days) by age group were 11.2 (7.7, 16.3) for navigated and 22.8 (14.9, 35.0) for non-navigated women <40; 21.6 (15.9, 29.2) for navigated and 33.7 (27.4, 41.4) for non-navigated women 40–49; 23.8 (17.0, 33.5) for navigated and 35.5 (28.4, 44.4) for non-navigated women 50–59; 11.9 (8.4, 16.9) for navigated and 36.2 (28.4, 46.2) for non-navigated women 60+.
Conclusions: The time required for navigated women to reach a definitive diagnosis following an abnormal screening was significantly shorter as compared to non-navigated women. While navigation was effective overall, the program proved to be more helpful for Hispanics and NHW than for NHB, especially among women aged 60+ years. Barriers preventing a rapid diagnostic resolution for NHB need to be explored further.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):B90.
Collapse
Affiliation(s)
| | - Nancy L. LaVerda
- 1The George Washington University Cancer Institute, Washington, DC
| | - Paul H. Levine
- 1The George Washington University Cancer Institute, Washington, DC
| | - Heather A. Young
- 1The George Washington University Cancer Institute, Washington, DC
| | | | | | | |
Collapse
|
43
|
Alshail E, Rutka JT, Drake JM, Hoffman HJ, Humphreys R, Phillips J, Cusimano M, Forte V, Papsin B, Holowka S. Utility of frameless stereotaxy in the resection of skull base and Basal cerebral lesions in children. Skull Base Surg 2011; 8:29-38. [PMID: 17171040 PMCID: PMC1656657 DOI: 10.1055/s-2008-1058588] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Since 1991, we have performed nearly 300 stereotactic procedures using the ISG viewing wand on a variety of cranial lesions in patients under 22 years of age. Of these, 38 procedures were performed on 34 patients for basal cerebral and skull base lesions. Our patients ranged in age from 3.5 months to 22 years with a mean age of 9.45 years. There were 18 females and 16 males. Twenty-one patients had basal cerebral lesions located in the thalamus (10), basal ganglia (2), third ventricle (2), and hypothalamus (7). Thirteen patients had skull base lesions located within the anterior optic apparatus (3), sella turcica (4), middle and posterior cranial fossae (4), and craniocervical region (2). Preoperative CT and/or MRI scan images were taken as a volume acquisition and transferred to the computer workstation utilizing the ISG Wand software. This workstation was transferred to the operating room where it was calibrated to a faro Surgicom arm which interfaces with the patient and the three-dimensional radiological image. The ISG Wand was utilized to plan the scalp and bone flaps and to select the optional trajectory to lesion. The surgical approaches which were specifically used in this series with the ISG Wand included transcallosal (15), pterional (5), frontal (3), subtemporal (4), transsphenoidal (3), temporal (3), tumor cyst shunt insertion (1), burr hole drainage (1), transoral (2), bifrontal (1), bifrontal mid facial (1), and transnasal (1). Although brain shift occurred following craniotomy and with brain retraction, the relative immobility of these lesions at the skull or cerebral base permitted an accurate targeting of all lesions with an error range of 1.0-2.5 mm throughout the entire procedure. This relatively precise intraoperative feedback led to more accurate recognition of tumor landmarks. It is the authors' impression that a more aggressive resection of these lesions was achieved than could be without the device. We conclude that a frameless stereotactic device such as the ISG Wand is particularly valuable in the approach to skull base and basal cerebral tumors in children.
Collapse
|
44
|
Klein CJ, Bernhard ME, Hoffman HJ, Cogen FR, Streisand R. Insulin regimen-associated differences in diets of preadolescents with type 1 diabetes. J Nutr Educ Behav 2011; 43:e4-e6. [PMID: 21550527 DOI: 10.1016/j.jneb.2011.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Revised: 03/06/2011] [Accepted: 03/16/2011] [Indexed: 05/30/2023]
|
45
|
Ardestani A, Parker B, Mathur S, Clarkson P, Pescatello LS, Hoffman HJ, Polk DM, Thompson PD. Relation of vitamin D level to maximal oxygen uptake in adults. Am J Cardiol 2011; 107:1246-9. [PMID: 21349488 DOI: 10.1016/j.amjcard.2010.12.022] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2010] [Revised: 12/15/2010] [Accepted: 12/15/2010] [Indexed: 12/17/2022]
Abstract
Low cardiorespiratory fitness and low serum 25-hydroxy vitamin D (25[OH]D) levels are associated with increased cardiovascular and all-cause mortality, but whether low 25(OH)D is independently associated with cardiorespiratory fitness in healthy adults is not known. We examined 25(OH)D levels and fitness in 200 healthy adults participating in a double-blind clinical trial investigating statins and muscle performance (STOMP study). Maximal aerobic exercise capacity (Vo₂(max)) was measured using metabolic gas analysis during graded treadmill exercise to exhaustion. 25(OH)D was measured using an enzyme-linked immunosorbent assay. Daily physical activity was assessed using the Paffenbarger Physical Activity Questionnaire. Serum 25(OH)D concentration was positively related to Vo₂(max) (r = 0.29, p = 0.0001), even after adjusting for relevant predictors (e.g., age, gender, and body mass index). There was also a significant interaction between 25(OH)D level and self-reported hours of moderate to vigorous physical activity (MVPA; p < 0.02). With each SD increase in 25(OH)D, Vo₂(max) increased by 2.6 ml/kg/min (p = 0.0001) when MVPA was low (16 hours/week) and 1.6 ml/kg/min (p <0.0004) when MVPA was moderate (35 hours/week) but only 0.01 ml/kg/min (p = 0.9) when MVPA was high (64 hours/week). In conclusion, serum 25(OH)D levels predict Vo₂(max) in adults; the effect is greatest in those with low levels of physical activity.
Collapse
|
46
|
Hoffman HJ, LaVerda NL, Levine PH, Young HA, Alexander LM, Patierno SR. Having health insurance does not eliminate race/ethnicity-associated delays in breast cancer diagnosis in the District of Columbia. Cancer 2011; 117:3824-32. [PMID: 21815134 DOI: 10.1002/cncr.25970] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2010] [Revised: 01/05/2011] [Accepted: 01/06/2011] [Indexed: 11/12/2022]
Abstract
BACKGROUND Delays in follow-up after breast cancer screening contribute to disparities in breast cancer outcomes. The objective of this research was to determine the impact of race/ethnicity and health insurance on diagnostic time, defined as number of days from suspicious finding to diagnostic resolution. METHODS This retrospective cohort study of 1538 women examined for breast abnormalities between 1998-2010 at 6 hospitals/clinics in the District of Columbia measured mean diagnostic times between non-Hispanic whites (NHWs), non-Hispanic blacks (NHBs), and Hispanics with private, government, or no health insurance by using a full-factorial ANOVA model. RESULTS Respective average--geometric mean (95% CI)--diagnostic times (in days) for NHWs, NHBs, and Hispanics were 16 (12, 21), 27 (23, 33), and 51 (35, 76) among privately insured; 12 (7, 19), 39 (32, 48), and 71 (48, 105) among government insured; 45 (17, 120), 60 (39, 92), and 67 (56, 79) among uninsured. Government insured NHWs had significantly shorter diagnostic times than government insured NHBs (P = .0003) and Hispanics (P < .0001). Privately insured NHWs had significantly shorter diagnostic times than privately insured NHBs (P = .03) and Hispanics (P < .0001). Privately insured NHBs had significantly shorter diagnostic times than uninsured NHBs (P = .03). CONCLUSIONS Insured minorities waited >2 times longer to reach their diagnostic resolution than insured NHWs. Having private health insurance increased the speed of diagnostic resolution in NHBs; however, their diagnostic time remained significantly longer than for privately insured NHWs. These results suggest diagnostic delays in minorities are more likely caused by other barriers associated with race/ethnicity than by insurance status.
Collapse
Affiliation(s)
- Heather J Hoffman
- Department of Epidemiology and Biostatistics, The George Washington University School of Public Health and Health Services, Washington, District of Columbia 20037, USA.
| | | | | | | | | | | | | |
Collapse
|
47
|
Hoffman HJ, Levine PH, Young HA, Alexander LM, Laverda NL, Patierno SR. Abstract PR-10: Impact of race, ethnicity and health insurance on delays in breast cancer diagnosis in the District of Columbia. Cancer Epidemiol Biomarkers Prev 2010. [DOI: 10.1158/1055-9965.disp-10-pr-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Background: Delays in follow-up after breast cancer screening are thought to contribute to disparities in breast cancer outcomes. The primary objective of this study is to determine the impact of race/ethnicity and type of health insurance on the diagnostic delay time, defined as the number of days from abnormal screening to definitive diagnosis.
Methods: This is a retrospective study of 976 women examined for breast cancer between 1998 and 2009 at six hospitals and clinics located in the District of Columbia. We used a full-factorial ANOVA model to test for significant differences in diagnostic delay time among non-Hispanic white (NHW), non-Hispanic black (NHB), and Hispanic women with private, government, or no health insurance. A log transformation was taken on the diagnostic delay time to normalize our data, and geometric means were estimated and compared.
Results: The average geometric mean (95% CI) diagnostic delay times were as follows: among those with private insurance, 15.9 (12.2,20.6) days for NHW, 27.0 (22.4,32.6) days for NHB, and 51.4 (34.8,76.0) days for Hispanic women; among those with government insurance, 11.9 (7.3,19.3) days for NHW, 39.5 (32.2,48.6) days for NHB, and 71.6 (47.8,107.1) days for Hispanic women; and among those without insurance, 44.5 (16.4,120.6) days for NHW, 59.7 (38.8,91.8) days for NHB, and 66.4 (55.8,79.1) days for Hispanic women. In fitting a full-factorial ANOVA model, we found that NHW women with government insurance had a significantly shorter delay in diagnosis than NHB (p=0.0003) and Hispanic (p<0.0001) women with government insurance. We also found that NHW women with private insurance had a significantly shorter delay in diagnosis than NHB (p=0.03) and Hispanic (p<0.0001) women with private insurance. However, there were no significant differences within the uninsured women (p>0.05). Finally, we found that NHB women with private insurance had a significantly shorter delay in diagnosis than uninsured NHB women (p=0.03).
Conclusions: NHB and Hispanic women with government or private insurance waited more than twice as long to reach their definitive diagnosis than NHW women with government or private insurance. Uninsured NHB women waited more than twice as long to reach their definitive diagnosis than NHB women with private insurance. Having private health insurance markedly increased the speed of diagnostic resolution in NHB women; however, the speed of diagnostic resolution remained significantly longer for NHB women with private insurance than for NHW women with private insurance. These results suggest that while both insurance and race/ethnicity affect diagnostic resolution, health insurance may not be the primary barrier to optimal diagnostic resolution in NHB women. It will be important to determine what other factors serve as the primary barriers, as well as if these delays affect the final breast cancer outcome for the patients.
Funding Mechanism: Grant Number 1 U01 CA116937; Patient Navigation Research Program (PNRP), Center for Research on Cancer Health Disparities (CRCHD), National Cancer Institute (NCI).
Citation Information: Cancer Epidemiol Biomarkers Prev 2010;19(10 Suppl):PR-10.
Collapse
|
48
|
Patierno SR, LaVerda NL, Hoffman HJ, Alexander LM, Levine PH, Young HA. Abstract B90: The District of Columbia citywide Patient Navigation Research Program (DC-PNRP): Preliminary descriptive findings. Cancer Epidemiol Biomarkers Prev 2010. [DOI: 10.1158/1055-9965.disp-10-b90] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Introduction: Minority breast cancer mortality rates in Washington, DC are among the Nation's highest. To address these disparities we instituted the DC Citywide Patient Navigation Research Program (DC-PNRP) - an inter-institutional collaboration that is one of 9 National PNRP sites funded by NCI/ACS to evaluate the effectiveness of patient navigation in reducing time from suspicious finding to diagnostic resolution and time from resolution to treatment initiation.
Study Procedures: A total of 1024 women, mostly minorities, have been enrolled from 8 recruitment sites at the point of suspicious finding. Utilizing a non-randomized design, 1240 concurrent, medical records-based controls were identified from 6 sites for comparison. Subject recruitment ended March 31,2010, but data collection continues on those women already enrolled. A unique framework of “network navigation” emerged whereby services were integrated across a city-wide network of unaffiliated healthcare sites. Navigators from a broad partnership of clinical and community sites were trained to work collaboratively within a city-wide network to enroll patients in the study and assure each receives timely, quality care. This “integrative navigation”model is collecting data addressing not only structural barriers to access to care (i.e., inadequate insurance, lack of transportation, etc.), but also psychosocial barriers (i.e., fear, medical mistrust, acculturation, etc.). Frequent trainings, efforts that promote increased communication between navigators, and sharing of information about community resources were implemented to enhance care coordination and to assure appropriate referral strategies between community outreach, screening, and treatment sites.
Results and Conclusion: Among controls, 7.66% were non-Hispanic whites (NHW), 35.24% were non-Hispanic blacks (NHB), 30.65% were Hispanic, and 26.45% were of other or unknown race/ethnicity. The corresponding percentages for navigated patients were 7.03%, 48.93%, 29.88%, and 14.16% indicating larger numbers of NHB and fewer with other/unknown race/ethnicity among the navigated patients. When examining age of subjects grouped by <40 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and >=80 years, respective proportions among controls were 7.10%, 37.98,28.15,16.29, 6.61, and 3.87%, while the distribution for navigated patients was: 20.70%, 32.03,24.41,14.06,5.57, and 3.22%, respectively, suggesting that navigated patients were slightly younger than controls. Household income level was generally unavailable for controls and for 35.54% of navigated patients. Proportions of navigated patients falling into the income categories <$10,000, $10-19,999, $20-29,999, $30-39,999, $40-49,999, and >=$50,000 are 14.06%, 13.38,9.38,9.18,4.59, and 13.87%, respectively, indicating fairly substantial numbers of low income patients. Among controls, 29.27% indicated they had no form of health insurance. The proportion was similar for navigated patients at 33.98%. Our data indicate we have comparable groups based on demographic attributes of navigated and control patients for our future analyses.
Funding Mechanism: Grant Number 1 U01 CA116937; Patient Navigation Research Program (PNRP), Center for Research on Cancer Health Disparities (CRCHD), National Cancer Institute (NCI).
Citation Information: Cancer Epidemiol Biomarkers Prev 2010;19(10 Suppl):B90.
Collapse
Affiliation(s)
| | | | | | | | - Paul H. Levine
- 1George Washington University Medical Center, Washington, DC
| | | |
Collapse
|
49
|
Ardestani A, Hoffman HJ, Cooper HA. Obesity and outcomes among patients with established atrial fibrillation. Am J Cardiol 2010; 106:369-73. [PMID: 20643247 DOI: 10.1016/j.amjcard.2010.03.036] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2009] [Revised: 03/17/2010] [Accepted: 03/17/2010] [Indexed: 12/31/2022]
Abstract
Atrial fibrillation (AF) and obesity have reached epidemic proportions. The impact of obesity on clinical outcomes in patients with established AF is unknown. We analyzed 2,492 patients in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Body mass index (BMI) was evaluated as a categorical variable (normal 18.5 to <25 kg/m(2), overweight 25 to <30 kg/m(2), obese >or=30 kg/m(2)). Rate of death from any cause was higher in the normal BMI group (5.8 per 100 patient-years) than in the overweight and obese groups (3.9 and 3.7, respectively). Cardiovascular death rate was highest in the normal BMI group (3.1 per 100 patient-years), lowest in the overweight group (1.5 per 100 patient-years), and intermediate in the obese group (2.1 per 100 patient-years). After adjustment for baseline factors, differences in risk of death from any cause were no longer significant. However, overweight remained associated with a lower risk of cardiovascular death (hazard ratio 0.47, p = 0.002). Obese patients were more likely to have an uncontrolled heart rate at rest, but rhythm-control strategy success was similar across BMI categories. In each BMI category, risk of death from any cause was similar for patients randomized to a rhythm- or rate-control strategy. In conclusion, in patients with established AF, overweight and obesity do not adversely affect overall survival. Obesity does not appear to affect the relative benefit of a rate- or rhythm-control strategy.
Collapse
|
50
|
Patierno SR, LaVerda NL, Alexander LM, D. E, Levine PH, Young HA, Hoffman HJ. Abstract 862: Network patient navigation: An integrative, longitudinal model to reduce breast cancer disparities. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Minority breast cancer mortality rates in Washington, DC are among the nation's highest. To address disparities we instituted the DC Citywide Patient Navigation Research Program (DC-PNRP) - an inter-institutional collaboration that is one of 9 National PNRP sites funded by NCI/ACS to evaluate the effectiveness of patient navigation in reducing barriers to obtaining health care while also addressing psychosocial factors.
Study Procedures: More than 1000 minority women have been enrolled from 7 recruitment sites at the point of suspicious finding to investigate whether patient navigation decreases time from suspicious breast finding to diagnostic resolution and time from diagnosis to treatment initiation. Utilizing a non-randomized design, concurrent, medical records-based controls have been identified. Data collection will extend through March 2010. A unique framework of “network navigation” emerged whereby services were integrated across a city-wide network of unaffiliated healthcare sites. Navigators from a broad partnership of clinical and community sites were trained to work collaboratively within a city-wide network to enroll patients in the study and assure each patient receives timely, quality care. This “integrative navigation” model is collecting data addressing not only structural barriers to access to care (i.e., inadequate insurance, lack of transportation, etc.), but also psychosocial barriers (i.e., fear, medical mistrust, acculturation, etc.). Frequent trainings, efforts that promote increased communication between navigators, and sharing of information about community resources were implemented to enhance care coordination and to assure appropriate referral strategies between community outreach, screening, and treatment sites.
Results and Conclusion: Implementation of DC-PNRP led us to broaden the original treatment-oriented navigation model to create a “Longitudinal Navigation” paradigm that follows the patient from outreach through survivorship. Data will be shown describing how this model addresses barriers to access and the underlying fragmentation of services that exist in DC for low-income uninsured or under-insured women. Data on the types and distribution of barriers will also be presented. This city-wide program serves as model for inter-institutional cooperation to improve health care access, particularly for the underserved.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 862.
Collapse
Affiliation(s)
| | | | | | - Ed D.
- 1George Washington University Medical Center, Washington, DC
| | - Paul H. Levine
- 1George Washington University Medical Center, Washington, DC
| | | | | |
Collapse
|